{"gene":"CYP11B1","run_date":"2026-04-28T17:28:53","timeline":{"discoveries":[{"year":1987,"finding":"CYP11B1 (P450c11) encodes a 479-amino-acid mature protein (plus a 24-residue mitochondrial signal sequence) that catalyzes steroid 11β-hydroxylation; cDNA cloning established the primary structure and chromosomal localization to 8q.","method":"cDNA cloning and sequencing; in vitro translation; chromosomal hybridization","journal":"Proceedings of the National Academy of Sciences of the United States of America","confidence":"High","confidence_rationale":"Tier 1 — original cDNA cloning with full sequence determination, foundational paper","pmids":["3499608"],"is_preprint":false},{"year":1989,"finding":"CYP11B1 and the paralog CYP11B2 each contain nine exons (introns in identical positions to CYP11A); the encoded proteins are 93% identical to each other, yet their 5'-flanking regions have diverged considerably, consistent with distinct transcriptional regulation. CYP11B2 transcripts were not detected in normal adrenal mRNA.","method":"Genomic library cloning, sequencing, and Northern blot","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 1 — complete genomic characterization with sequence analysis, foundational study","pmids":["2592361"],"is_preprint":false},{"year":1990,"finding":"CYP11B1 (P-45011β) expressed in COS-7 cells exhibits exclusively 11β-hydroxylase activity, converting 11-deoxycortisol to cortisol, but fails to catalyze aldosterone or 18-oxocortisol synthesis, distinguishing it functionally from CYP11B2.","method":"Transient transfection of full-length cDNA in COS-7 cells; steroid conversion assay","journal":"FEBS letters","confidence":"High","confidence_rationale":"Tier 1 — direct enzymatic activity demonstrated in heterologous expression system","pmids":["2401360"],"is_preprint":false},{"year":1991,"finding":"A single base substitution in CYP11B1 exon 8 (Arg-448→His, within the heme-binding peptide containing the cysteine heme-ligand) abolishes 11β-hydroxylase activity, demonstrating that Arg-448 is essential for enzymatic function.","method":"PCR-selective amplification of CYP11B1, DNA sequencing; family linkage","journal":"The Journal of clinical investigation","confidence":"High","confidence_rationale":"Tier 2 — identified functionally critical residue in heme-binding domain with strong genetic segregation evidence","pmids":["2022736"],"is_preprint":false},{"year":1992,"finding":"CYP11B1 encodes a protein with only 11β-hydroxylase activity; the hybrid gene in glucocorticoid-suppressible hyperaldosteronism (GSH) has CYP11B1 5'-regulatory and coding sequences fused to 3'-CYP11B2 coding sequences. Transfection experiments showed that hybrids retaining ≤3 CYP11B1 exons could synthesize aldosterone near wild-type CYP11B2 levels, while hybrids containing ≥5 CYP11B1 exons could not, mapping aldosterone synthase determinants to exons 4–9 of CYP11B2.","method":"Transfection of hybrid cDNAs into COS-1 cells; aldosterone synthesis assay","journal":"Proceedings of the National Academy of Sciences of the United States of America","confidence":"High","confidence_rationale":"Tier 1 — reconstitution by transfection of defined hybrid constructs with enzymatic readout","pmids":["1518866"],"is_preprint":false},{"year":1992,"finding":"Hereditary hypertension (glucocorticoid-remediable aldosteronism) is caused by chimeric gene duplications that fuse CYP11B1 regulatory sequences to CYP11B2 coding sequences, resulting in ectopic aldosterone synthase activity regulated by ACTH; crossing-over occurs between introns 2 and 4.","method":"Southern blot, genomic PCR, chimeric gene characterization in 12 kindreds","journal":"Nature genetics","confidence":"High","confidence_rationale":"Tier 2 — direct genetic demonstration of regulatory/coding domain swap with functional consequence replicated across 12 families","pmids":["1303253"],"is_preprint":false},{"year":1992,"finding":"CYP11B1 exon 7 frameshift (2-bp insertion at codon 394) destroys the heme-binding domain and completely abolishes 11β-hydroxylase activity.","method":"Gene cloning and sequencing; inference from protein structure","journal":"The Journal of clinical endocrinology and metabolism","confidence":"Medium","confidence_rationale":"Tier 2 — frameshift mutation directly explains complete loss of function; mechanistic link to heme-binding domain established","pmids":["1430088"],"is_preprint":false},{"year":1992,"finding":"CYP11B1 promoter activity requires a CRE-like Ad1 element and upstream elements Ad3/Ad4 for full cAMP-dependent transcription; both elements must cooperate for maximal cAMP response in steroidogenic cells.","method":"Transient transfection reporter assay with deletion/mutation constructs; in vitro transcription; CREB/nuclear factor binding assays","journal":"Journal of biochemistry","confidence":"High","confidence_rationale":"Tier 2 — multiple orthogonal approaches (reporter assay, in vitro transcription, EMSA) in same study","pmids":["1336011"],"is_preprint":false},{"year":1993,"finding":"All five known missense mutations causing 11β-hydroxylase deficiency (including Arg-448→His, Arg-384→Gly, and three others) abolish enzymatic activity when expressed in vitro; mutations cluster in exons 6–8, suggesting these regions harbor functionally critical residues.","method":"In vitro transfection assay (COS cell expression) of mutant cDNAs; steroid conversion measurement","journal":"Proceedings of the National Academy of Sciences of the United States of America","confidence":"High","confidence_rationale":"Tier 1 — direct in vitro enzymatic assay of multiple loss-of-function mutations, establishing exon 6–8 as functionally critical","pmids":["8506298"],"is_preprint":false},{"year":1993,"finding":"Ad4BP (steroidogenic cell-specific transcription factor, now SF-1/NR5A1) binds the Ad4 cis-element in the CYP11B promoter and is required for cAMP-dependent, steroidogenic cell-specific transcription; its absence in non-steroidogenic cells accounts for lack of CYP11B expression there.","method":"Transient transfection reporter assay; immunoblot; cotransfection of Ad4BP expression vector","journal":"Molecular endocrinology","confidence":"High","confidence_rationale":"Tier 2 — gain-of-function cotransfection plus protein immunoblot demonstrate direct role of Ad4BP","pmids":["8247022"],"is_preprint":false},{"year":1993,"finding":"A nonsense mutation (Trp116→Stop) in CYP11B1 exon 2 results in complete absence of 11β-hydroxylase activity in mitochondria of transfected COS-7 cells, demonstrating that intact protein is required for activity.","method":"PCR, sequencing, RFLP, COS-7 cell transfection and enzyme activity assay","journal":"The Journal of clinical endocrinology and metabolism","confidence":"High","confidence_rationale":"Tier 1 — direct demonstration of loss of function via heterologous expression","pmids":["7903314"],"is_preprint":false},{"year":1994,"finding":"Two Ad4 sites in the distal promoter of bovine CYP11B (−1.5 to −1.1 kb) confer steroidogenic cell-specific and cAMP-stimulated transcriptional activation through Ad4BP; distal and proximal promoters interact in a gene-specific manner.","method":"Transient transfection of CAT reporter constructs with distal promoter fragments in steroidogenic and non-steroidogenic cells","journal":"Journal of biochemistry","confidence":"Medium","confidence_rationale":"Tier 2 — defined cis-element mapped by reporter deletion; cell-type specificity confirmed","pmids":["7798178"],"is_preprint":false},{"year":1995,"finding":"CYP11B1 expressed in COS-1 cells and stably in V79 Chinese hamster cells retains 11β-hydroxylase activity without requiring exogenous electron-transfer proteins, indicating that hamster cells provide sufficient endogenous adrenodoxin/adrenodoxin reductase-like activity.","method":"cDNA cloning; COS-7 transient transfection; V79 stable transfection; Northern blot; steroid hydroxylase activity assay","journal":"Endocrine research","confidence":"Medium","confidence_rationale":"Tier 1 — direct enzymatic assay in two expression systems","pmids":["7588408"],"is_preprint":false},{"year":1995,"finding":"CYP11B1 (P450c11β) metabolizes and bioactivates the adrenotoxic xenobiotic MeSO2-DDE, establishing that this mitochondrial steroidogenic P450 can also perform xenobiotic metabolism; activity demonstrated by correlation with DOC metabolism induction by forskolin, inhibition of P450c11-dependent activities by MeSO2-DDE, and COS cell transfection experiments.","method":"Correlation of enzyme induction; inhibition assays in Y1 and Kin-8 cells; COS cell transfection with CYP11B1 cDNA followed by MeSO2-DDE metabolism assay","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 1 — multiple orthogonal approaches including reconstitution in COS cells demonstrate xenobiotic substrate activity","pmids":["7673111"],"is_preprint":false},{"year":1995,"finding":"An AP-1 transcription factor complex (containing JunD and a Fos-related protein) binds adjacent to the Ad4BP site in the rat CYP11B1 promoter; AP-1 binding suppresses Ad4BP binding, and the AP-1 site (not the Ad4 site) drives transcriptional activation in zona fasciculata cells. AP-1 factor is present in nuclei of CYP11B1-expressing zona fasciculata cells but not in other zones.","method":"Transient transfection with promoter mutants in Y1 cells; EMSA with nuclear extracts; immunohistochemistry","journal":"Molecular and cellular biology","confidence":"High","confidence_rationale":"Tier 2 — mutational analysis plus EMSA plus immunohistochemistry provide convergent mechanistic evidence","pmids":["7565753"],"is_preprint":false},{"year":1996,"finding":"Point mutations in the putative I-helix of CYP11B1 (e.g., Val-320→Ala, the CYP11B2-specific residue) confer aldosterone synthesis (18-oxidase activity) on CYP11B1, while the reciprocal CYP11B2 mutations at positions 296, 301, 302, and 320 elevate its 11β-hydroxylase activity and diminish aldosterone synthase activity, identifying this region as determining regioselectivity.","method":"Site-directed mutagenesis; COS cell expression; steroid product profiling","journal":"Endocrine research","confidence":"High","confidence_rationale":"Tier 1 — reconstitution with mutagenesis; defined amino acid positions controlling enzymatic specificity","pmids":["8969896"],"is_preprint":false},{"year":1997,"finding":"Non-classic 11β-hydroxylase deficiency is caused by partial-loss-of-function missense mutations in CYP11B1 (e.g., N133H, T319M, P42S) that reduce but do not abolish enzymatic activity when expressed in vitro, establishing a genotype–phenotype correlation.","method":"In vitro expression in COS cells; steroid conversion assay","journal":"Human molecular genetics","confidence":"High","confidence_rationale":"Tier 1 — direct enzymatic quantification of multiple mutant enzymes","pmids":["9302260"],"is_preprint":false},{"year":1998,"finding":"Replacement of CYP11B1 residues at positions 320 (Val→Ala) and 335 with CYP11B2-specific residues confers 18-oxidase activity (~20% of CYP11B2 WT), converting CYP11B1 into a partial aldosterone synthase; combining substitutions at positions 296, 301, 302, 320, 335, and 339 did not further enhance activity. The region spanning residues 301–335 constitutes part of the substrate-binding site.","method":"Site-directed mutagenesis; chimeric protein construction; COS cell transfection; steroid product analysis","journal":"European journal of biochemistry","confidence":"High","confidence_rationale":"Tier 1 — systematic reciprocal mutagenesis defining substrate-binding site residues","pmids":["9546661"],"is_preprint":false},{"year":1998,"finding":"CYP11B1 hybrid enzymes with CYP11B2 residues at Ser-288 and Val-320 can catalyze conversion of 11-deoxycortisol to cortisol, 18-hydroxycortisol, and 18-oxocortisol; additional substitutions from CYP11B2 exons 4–6 further enhance 18-hydroxylcortisol and 18-oxocortisol production.","method":"Recombinant hybrid cDNA construction; cell transfection; steroid product measurement","journal":"The Journal of clinical endocrinology and metabolism","confidence":"High","confidence_rationale":"Tier 1 — defined hybrid enzymes expressed and enzymatically characterized","pmids":["9814482"],"is_preprint":false},{"year":1998,"finding":"CYP11B1 expressed in E. coli retains 11β-hydroxylase activity; Dahl salt-resistant rat CYP11B1 (DR-CYP11B1) has decreased 18-hydroxylase and 19-hydroxylase activities compared to WT; the double mutation V381L/I384L accounts for decreased 18-OHase activity, and V443M accounts for decreased 19-OHase activity.","method":"Bacterial expression; site-directed mutagenesis; steroid conversion assays","journal":"European journal of biochemistry","confidence":"High","confidence_rationale":"Tier 1 — E. coli reconstitution with mutagenesis defining key residues for 18-OHase and 19-OHase activities","pmids":["9874258"],"is_preprint":false},{"year":1998,"finding":"ACTH-stimulated transcription of rat CYP11B1 requires an AP-1 binding site in the 5'-flanking region; corticotropin induces compositional changes in AP-1 factors (increasing c-Jun/c-Fos over constitutive JunD/Fra-2) via a cAMP-dependent pathway, and c-Jun/c-Fos overexpression transactivates CYP11B1 more strongly than other combinations.","method":"Transient transfection with promoter mutants; AP-1 supershift EMSA; cAMP treatment; in vivo corticotropin treatment + mRNA analysis","journal":"European journal of biochemistry","confidence":"High","confidence_rationale":"Tier 2 — multiple orthogonal methods (transfection, EMSA, in vivo) defining mechanism of ACTH-induced transcription","pmids":["9746364"],"is_preprint":false},{"year":1999,"finding":"CYP11B1 and CYP11A1 co-expressed in COS-1 cells compete for reducing equivalents from the endogenous electron-transfer system; excess adrenodoxin resolves this competition. Bovine CYP11B1 co-expressed with CYP11A1 and adrenodoxin shows stimulated 11β-hydroxylation but reduced 18-hydroxycorticosterone and aldosterone formation, indicating functional interaction between the mitochondrial P450 enzymes.","method":"Co-transfection of COS-1 cells; steroid product analysis with and without exogenous adrenodoxin","journal":"European journal of biochemistry","confidence":"Medium","confidence_rationale":"Tier 2 — competition for electron donor established by co-transfection with adrenodoxin rescue","pmids":["10411633"],"is_preprint":false},{"year":2000,"finding":"The CRE/Ad1 element in the hCYP11B1 promoter is required for both basal expression and agonist (angiotensin II, potassium, cAMP, forskolin) responsiveness; mutation of this element reduces basal activity and agonist response. CREB, ATF-1, and ATF-2 bind this element in vitro, with ATF-2 complexes seen in adrenocortical nuclear extracts.","method":"Transient transfection reporter assays in H295R cells; EMSA with in vitro prepared and nuclear extract proteins","journal":"Endocrine research","confidence":"High","confidence_rationale":"Tier 2 — mutational analysis plus EMSA with identified transcription factors","pmids":["11196473"],"is_preprint":false},{"year":2001,"finding":"Adrenodoxin mutants with C-terminal truncation and introduction of Trp at position 112 (e.g., S112W) show markedly faster reduction kinetics with CYP11A1 but not CYP11B1, demonstrating that CYP11A1 and CYP11B1 have distinct requirements for adrenodoxin-mediated electron transfer. CYP11B1 reduction rate constants were similar across adrenodoxin mutants, unlike CYP11A1.","method":"Stopped-flow kinetics of CO-complex formation; substrate conversion assays; site-directed mutagenesis of adrenodoxin","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 1 — quantitative kinetic analysis with multiple adrenodoxin mutants, demonstrating differential protein-protein interaction requirements","pmids":["11459837"],"is_preprint":false},{"year":2002,"finding":"The steroidogenic factor SF-1 (Ad4BP/NR5A1) positively regulates CYP11B1 transcription (increasing reporter activity) via the Ad4 element in the promoter; mutation of the Ad4 element blocks agonist stimulation of CYP11B1 but not CYP11B2. EMSA shows SF-1 binds the CYP11B1 Ad4 element. Conversely, SF-1 overexpression inhibits CYP11B2 expression.","method":"Transient transfection reporter assays; EMSA; SF-1 siRNA knockdown; doxycycline-inducible SF-1 overexpression in H295R cells","journal":"Journal of molecular endocrinology","confidence":"High","confidence_rationale":"Tier 2 — gain- and loss-of-function plus EMSA with defined SF-1 binding site","pmids":["11932209"],"is_preprint":false},{"year":2005,"finding":"CYP11B1 missense mutations W116C and L299P reduce enzymatic activity to ~3% and ~1% of WT respectively, and ΔF438 abolishes activity entirely; 3D modeling suggests W116C disrupts conformational change for substrate access/product release, L299P alters I-helix positioning relative to heme, and ΔF438 causes steric disarrangement of the heme group.","method":"COS-7 cell in vitro expression; steroid conversion assay; 3D computational modeling","journal":"The Journal of clinical endocrinology and metabolism","confidence":"High","confidence_rationale":"Tier 1+2 — direct enzymatic quantification combined with structural modelling of multiple mutations","pmids":["15755848"],"is_preprint":false},{"year":2006,"finding":"PCB126 up-regulates CYP11B1 and CYP11B2 mRNA not through AhR-mediated transcriptional activation but by stabilizing mRNA post-transcriptionally; an internal region of CYP11B1 mRNA (nucleotides 881–1285) is important for PCB126-mediated transcript stabilization.","method":"RNA degradation assays; promoter analysis; AhR antagonist treatment; mRNA stability assays with defined CYP11B1 mRNA fragments in H295R cells","journal":"Endocrinology","confidence":"High","confidence_rationale":"Tier 2 — RNA stability mechanism defined with mRNA region mapping","pmids":["16396990"],"is_preprint":false},{"year":2007,"finding":"Co-expression of adrenodoxin and adrenodoxin reductase with CYP11B1 in fission yeast (S. pombe) increases 11β-hydroxylation activity 3.4-fold; site-directed mutagenesis at position 78 (isoleucine) of CYP11B1 confers highest hydroxylation activity, demonstrating that the redox partner system and specific amino acid identity at position 78 are rate-limiting for cortisol production.","method":"S. pombe expression system; site-directed mutagenesis; cortisol production measurement","journal":"Journal of biotechnology","confidence":"High","confidence_rationale":"Tier 1 — reconstitution with co-expression and mutagenesis demonstrating electron-transfer dependence and key residue","pmids":["17935813"],"is_preprint":false},{"year":2008,"finding":"Purified recombinant human CYP11B1 (co-expressed with GroES/GroEL chaperones in E. coli) retains 11β-hydroxylase activity with ~75% NADPH coupling efficiency for both 11-deoxycortisol and 11-deoxycorticosterone substrates. Biacore and stopped-flow measurements indicate CYP11B1 possesses more than one binding site for adrenodoxin, suggesting formation of multiple productive complexes.","method":"E. coli expression with chaperone co-expression; purification to homogeneity; mass spectrometry; substrate conversion assays; Biacore (SPR); stopped-flow spectroscopy; CD spectroscopy","journal":"The FEBS journal","confidence":"High","confidence_rationale":"Tier 1 — reconstituted purified enzyme with multiple biophysical and biochemical methods","pmids":["18215163"],"is_preprint":false},{"year":2008,"finding":"Cyp11b1 knockout mice (exons 3–7 replaced by ECFP cDNA) lack 11β-hydroxylase activity (confirmed by urinary steroid profiles and absent immunostaining), exhibit glucocorticoid deficiency, mineralocorticoid excess (DOC accumulation), adrenal hyperplasia, mild hypertension, hypokalemia, glucose intolerance, and female infertility due to anovulation.","method":"Targeted gene knockout (exon replacement); urinary steroid profiling; immunocytochemistry; blood pressure measurement; reproductive phenotyping","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 2 — clean genetic knockout with multiple defined phenotypic readouts establishing in vivo functions","pmids":["19029289"],"is_preprint":false},{"year":2010,"finding":"Novel CYP11B1 missense mutations causing classic 11β-OHD (W116G, A165D, K254_A259del) show absent or near-absent 11β-hydroxylase activity; mutations causing non-classic 11β-OHD (P159L, M88I) show partial activity (~25% and ~40% of WT respectively), demonstrating a direct correlation between residual enzyme activity level and disease severity.","method":"COS7 cell in vitro expression system; steroid conversion assay; 3D computational modeling","journal":"The Journal of clinical endocrinology and metabolism","confidence":"High","confidence_rationale":"Tier 1 — quantitative enzymatic analysis of 7 mutations with clear genotype-phenotype correlation","pmids":["20089618"],"is_preprint":false},{"year":2011,"finding":"The Ad5/SF-1 binding element in the CYP11B1 core promoter is required for basal expression; ERRα is the transcription factor that interacts with the Ad5 site during basal expression. Insertion of an L1 transposable element (CYP11B1-L1.2) between the Alu elements and the proximal core promoter suppresses Alu enhancer activity on CYP11B1; deletion of CYP11B1-L1.2 greatly increases promoter activity.","method":"Promoter deletion/mutation reporter assays; transcription factor identification by EMSA; Alu and L1 element functional analysis; luciferase assays in H295R cells","journal":"Steroids","confidence":"Medium","confidence_rationale":"Tier 2 — defined cis-elements and identified ERRα as binding transcription factor with functional assays","pmids":["22079243"],"is_preprint":false},{"year":2011,"finding":"Nonhydroxylated flavones (3',4'-dimethoxyflavone, α- and β-naphthoflavone) up-regulate CYP11B1 expression and cortisol production in H295R cells; this induction requires the Ad5 element (−121/−106) in the CYP11B1 promoter and is partially dependent on PKA signaling (sensitive to H-89) but independent of AhR and ERK1/2 signaling.","method":"H295R cell model; qRT-PCR; promoter reporter assays with Ad5 mutations; pharmacological inhibitors; western blot","journal":"Toxicology and applied pharmacology","confidence":"Medium","confidence_rationale":"Tier 2 — promoter element mapping combined with pharmacological dissection of signaling pathway","pmids":["22172629"],"is_preprint":false},{"year":2014,"finding":"miR-10b is a hypoxia-inducible microRNA that negatively regulates CYP11B1 and CYP11B2 at the post-transcriptional level by targeting their 3'-UTRs; luciferase reporter assays with 3'-UTR constructs and miRNA overexpression/knockdown confirmed this interaction in H295R cells.","method":"miRNA array; in silico target prediction; luciferase 3'-UTR reporter assays; miR-10b overexpression and knockdown in H295R cells","journal":"Marine pollution bulletin","confidence":"Medium","confidence_rationale":"Tier 2 — validated by 3'-UTR reporter assay and overexpression/knockdown experiments","pmids":["24768260"],"is_preprint":false},{"year":2015,"finding":"An E. coli whole-cell system co-expressing CYP11B1, adrenodoxin, and adrenodoxin reductase selectively converts 11-deoxycortisol to cortisol; CYP11B1 expression was enhanced 3.3-fold by mutagenesis of Gly-23→Arg, improving cortisol yield 2.6-fold. Additional Adx copies further accelerated conversion, demonstrating that electron-transfer chain stoichiometry is rate-limiting.","method":"E. coli whole-cell biocatalysis; site-directed mutagenesis; copy-number variation of Adx; LC-MS cortisol quantification; directed evolution screening","journal":"Microbial cell factories","confidence":"High","confidence_rationale":"Tier 1 — reconstituted three-component system with mutagenesis and quantitative optimization","pmids":["25880059"],"is_preprint":false},{"year":2017,"finding":"DNA hypomethylation of the CYP11B1 promoter is associated with increased CYP11B1 expression and cortisol overproduction in cortisol-producing adenomas (CPA); reporter assays confirmed that DNA methylation directly reduces CYP11B1 promoter activity. Somatic mutations in PRKACA or GNAS in CPA are associated with significant CYP11B1 promoter hypomethylation.","method":"Bisulfite sequencing of CYP11B1 promoter; methylated reporter assay; comparison between CPA, adjacent adrenal, and white blood cells; somatic mutation genotyping","journal":"Scientific reports","confidence":"High","confidence_rationale":"Tier 2 — direct reporter assay demonstrating methylation represses CYP11B1 promoter, with in vivo correlation to adenoma somatic mutations","pmids":["28894201"],"is_preprint":false},{"year":2017,"finding":"Computational 3D modeling of 25 CYP11B1 missense mutations reveals that modifications in the heme-binding site (R374W, R448C), substrate-binding site (W116C), or protein stability (L299P, G267S) predict severe 11β-hydroxylase deficiency, providing a structural basis for genotype-severity correlation in the largest cohort (108 patients) studied to date.","method":"Homology-based computational structural modeling; clinical/hormonal correlation with genotype in 108 patients","journal":"Proceedings of the National Academy of Sciences of the United States of America","confidence":"Medium","confidence_rationale":"Tier 4 computational + Tier 2 clinical correlation — large cohort provides strong validation but mechanism inferred by modeling","pmids":["28228528"],"is_preprint":false}],"current_model":"CYP11B1 encodes a mitochondrial cytochrome P450 (11β-hydroxylase) that catalyzes the final step of cortisol biosynthesis by converting 11-deoxycortisol to cortisol via 11β-hydroxylation, receiving electrons from NADPH through adrenodoxin reductase and adrenodoxin (with which it forms multiple productive complexes); its substrate-binding site and regioselectivity are determined by residues in the I-helix region (especially positions 301–335), its heme-binding domain (Cys and Arg-448) is essential for catalysis, its transcription in zona fasciculata is driven by cooperative action of the CRE/Ad1 element with CREB/ATF factors, the Ad4/Ad5 element with SF-1/ERRα, and an AP-1 complex, while post-transcriptional regulation occurs through mRNA stabilization (e.g., by PCBs via an internal mRNA element) and microRNA targeting (miR-10b at the 3'-UTR), and epigenetic control by promoter DNA methylation modulates expression in adrenal adenomas."},"narrative":{"teleology":[{"year":1987,"claim":"Establishing that CYP11B1 encodes a mitochondrial cytochrome P450 with steroid 11β-hydroxylase activity resolved the molecular identity of the enzyme responsible for cortisol's final biosynthetic step.","evidence":"cDNA cloning, sequencing, and chromosomal mapping to 8q from bovine/human adrenal libraries","pmids":["3499608"],"confidence":"High","gaps":["Enzymatic activity not yet demonstrated from the cloned cDNA","Paralogous gene (CYP11B2) not yet distinguished"]},{"year":1990,"claim":"Functional expression in heterologous cells demonstrated that CYP11B1 has exclusively 11β-hydroxylase activity (cortisol synthesis) and cannot synthesize aldosterone, definitively distinguishing it from CYP11B2 despite 93% sequence identity.","evidence":"COS-7 transient transfection with steroid conversion assays for CYP11B1 vs CYP11B2; genomic structure comparison","pmids":["2401360","2592361"],"confidence":"High","gaps":["Structural determinants of substrate selectivity unknown","Electron-transfer partner requirements not quantified"]},{"year":1993,"claim":"Systematic expression of disease-causing mutations revealed that residues in exons 6–8—including the heme-ligand-proximal Arg-448—are essential for catalysis, mapping functionally critical domains before any crystal structure was available.","evidence":"In vitro COS cell expression of five missense and one nonsense mutation with steroid conversion assays; family segregation studies","pmids":["8506298","2022736","7903314"],"confidence":"High","gaps":["Three-dimensional structure not determined","Mechanism by which individual residues contribute to catalysis unresolved"]},{"year":1993,"claim":"Identification of Ad4BP (SF-1) as the steroidogenic cell–specific transcription factor driving CYP11B1 promoter activity via the Ad4 element explained why this gene is expressed only in adrenocortical cells.","evidence":"Cotransfection of Ad4BP expression vector restores CYP11B1 reporter activity in non-steroidogenic cells; immunoblot confirmation","pmids":["8247022","1336011"],"confidence":"High","gaps":["Additional cis-elements (CRE/Ad1, AP-1) not yet integrated into a unified regulatory model","In vivo chromatin context not assessed"]},{"year":1996,"claim":"Reciprocal mutagenesis at I-helix positions (296, 301, 302, 320, 335) between CYP11B1 and CYP11B2 showed that a handful of residues in this region determine whether the enzyme performs 11β-hydroxylation or aldosterone synthesis, resolving the structural basis of paralog divergence.","evidence":"Site-directed mutagenesis with COS cell expression and steroid product profiling","pmids":["8969896","9546661"],"confidence":"High","gaps":["Crystal structure needed to explain how these residues position substrate","Residues 301–335 necessary but possibly not sufficient for full selectivity switch"]},{"year":1998,"claim":"ACTH-stimulated CYP11B1 transcription was shown to operate through an AP-1 site whose factor composition shifts from constitutive JunD/Fra-2 to induced c-Jun/c-Fos via cAMP, integrating hormonal signaling with zona fasciculata–specific expression.","evidence":"Promoter mutant transfection, AP-1 supershift EMSA, and in vivo ACTH treatment in rat adrenal","pmids":["9746364","7565753"],"confidence":"High","gaps":["Chromatin remodeling events at the endogenous locus not examined","Relative contribution of AP-1 vs CRE/Ad1 to ACTH response not quantified in human cells"]},{"year":2001,"claim":"Stopped-flow kinetics with adrenodoxin mutants revealed that CYP11B1 and CYP11A1 have distinct electron-transfer requirements, and Biacore data later showed CYP11B1 possesses more than one adrenodoxin-binding site, explaining how multiple productive complexes form.","evidence":"Stopped-flow CO-complex kinetics with adrenodoxin variants; SPR (Biacore) binding of purified CYP11B1","pmids":["11459837","18215163"],"confidence":"High","gaps":["Stoichiometry and structural arrangement of the multi-adrenodoxin complex not resolved","In vivo relevance of multiple binding sites not tested"]},{"year":2008,"claim":"A Cyp11b1-knockout mouse confirmed the enzyme's non-redundant in vivo role: loss of 11β-hydroxylase causes glucocorticoid deficiency, DOC-driven mineralocorticoid excess with hypertension, adrenal hyperplasia, and female infertility, phenocopying human 11β-hydroxylase deficiency.","evidence":"Targeted exon 3–7 replacement; urinary steroid profiling, blood pressure, reproductive phenotyping","pmids":["19029289"],"confidence":"High","gaps":["Rescue experiments not performed","Sex-specific phenotypic mechanisms (anovulation) not dissected molecularly"]},{"year":2010,"claim":"Quantitative in vitro activity measurement of classic and non-classic disease mutations established that residual enzyme activity directly predicts clinical severity, providing a mechanistic framework for genotype–phenotype correlation.","evidence":"COS7 expression of seven mutations; steroid conversion assay correlated with clinical phenotype","pmids":["20089618","9302260"],"confidence":"High","gaps":["Protein stability versus catalytic impairment not distinguished for all mutations","Effects of compound heterozygosity on net activity not modeled"]},{"year":2017,"claim":"Epigenetic regulation was added to the CYP11B1 regulatory model when promoter DNA hypomethylation was shown to increase CYP11B1 expression in cortisol-producing adenomas, linking somatic PRKACA/GNAS mutations to epigenetic de-repression.","evidence":"Bisulfite sequencing of adenoma vs. normal adrenal; methylated reporter assay; somatic mutation genotyping","pmids":["28894201"],"confidence":"High","gaps":["Causal direction (does mutation cause demethylation or vice versa?) not established by intervention","Methylation dynamics during normal adrenal zonation unexplored"]},{"year":null,"claim":"No experimentally determined crystal or cryo-EM structure of human CYP11B1 has been reported; structural understanding still relies on homology models, leaving the precise geometry of the substrate-binding pocket and the multi-adrenodoxin interaction surface unresolved.","evidence":"","pmids":[],"confidence":"High","gaps":["Experimental 3D structure not available","Molecular dynamics of substrate access channel and product release not characterized","In vivo regulation by adrenal zonation-specific chromatin architecture not determined"]}],"mechanism_profile":{"molecular_activity":[{"term_id":"GO:0016491","term_label":"oxidoreductase activity","supporting_discovery_ids":[0,2,8,15,17,19,28,29,30]},{"term_id":"GO:0140096","term_label":"catalytic activity, acting on a protein","supporting_discovery_ids":[2,15,17,19,28]}],"localization":[{"term_id":"GO:0005739","term_label":"mitochondrion","supporting_discovery_ids":[0,10,29]}],"pathway":[{"term_id":"R-HSA-1430728","term_label":"Metabolism","supporting_discovery_ids":[0,2,15,17,19,28,29,34]},{"term_id":"R-HSA-1643685","term_label":"Disease","supporting_discovery_ids":[3,5,6,8,16,30,36]}],"complexes":[],"partners":["FDX1","FDXR","NR5A1","CREB1","ATF2","JUN","ESRRA"],"other_free_text":[]},"mechanistic_narrative":"CYP11B1 is a mitochondrial cytochrome P450 (steroid 11β-hydroxylase) that catalyzes the final step of cortisol biosynthesis by converting 11-deoxycortisol to cortisol, receiving electrons from NADPH via the adrenodoxin reductase–adrenodoxin chain, with which it forms multiple productive complexes [PMID:18215163, PMID:2401360]. Substrate regioselectivity—distinguishing CYP11B1 (11β-hydroxylase) from the paralog CYP11B2 (aldosterone synthase)—is determined by a small cluster of residues in the I-helix region (positions 301–335), where single substitutions can confer 18-oxidase activity on CYP11B1 [PMID:9546661, PMID:8969896]. Zona fasciculata–specific transcription is driven by cooperative action of a CRE/Ad1 element bound by CREB/ATF factors, an Ad4 element bound by SF-1, an Ad5 element occupied by ERRα, and an AP-1 complex whose composition shifts upon ACTH stimulation, while post-transcriptional regulation occurs through mRNA stabilization and miR-10b–mediated repression, and promoter DNA methylation modulates expression in cortisol-producing adenomas [PMID:11196473, PMID:8247022, PMID:22079243, PMID:9746364, PMID:24768260, PMID:28894201]. Loss-of-function mutations cause congenital adrenal hyperplasia due to 11β-hydroxylase deficiency, with residual enzymatic activity directly correlating with clinical severity, and Cyp11b1-knockout mice recapitulate glucocorticoid deficiency, mineralocorticoid excess, and hypertension [PMID:20089618, PMID:19029289]."},"prefetch_data":{"uniprot":{"accession":"P15538","full_name":"Cytochrome P450 11B1, mitochondrial","aliases":["CYPXIB1","Cytochrome P-450c11","Cytochrome P450C11","Steroid 11-beta-hydroxylase, CYP11B1"],"length_aa":503,"mass_kda":57.6,"function":"A cytochrome P450 monooxygenase involved in the biosynthesis of adrenal corticoids (PubMed:12530636, PubMed:1518866, PubMed:1775135, PubMed:18215163, PubMed:23322723). Catalyzes a variety of reactions that are essential for many species, including detoxification, defense, and the formation of endogenous chemicals like steroid hormones. Steroid 11beta, 18- and 19-hydroxylase with preferred regioselectivity at 11beta, then 18, and lastly 19 (By similarity). Catalyzes the hydroxylation of 11-deoxycortisol and 11-deoxycorticosterone (21-hydroxyprogesterone) at 11beta position, yielding cortisol or corticosterone, respectively, but cannot produce aldosterone (PubMed:12530636, PubMed:1518866, PubMed:1775135, PubMed:18215163, PubMed:23322723). Mechanistically, uses molecular oxygen inserting one oxygen atom into a substrate for hydroxylation and reducing the second into a water molecule. Two electrons are provided by NADPH via a two-protein mitochondrial transfer system comprising flavoprotein FDXR (adrenodoxin/ferredoxin reductase) and nonheme iron-sulfur protein FDX1 or FDX2 (adrenodoxin/ferredoxin) (PubMed:18215163). Due to its lack of 18-oxidation activity, it is incapable of generating aldosterone (PubMed:23322723). Could also be involved in the androgen metabolic pathway (Probable)","subcellular_location":"Mitochondrion inner membrane","url":"https://www.uniprot.org/uniprotkb/P15538/entry"},"depmap":{"release":"DepMap","has_data":true,"is_common_essential":false,"resolved_as":"","url":"https://depmap.org/portal/gene/CYP11B1","classification":"Not Classified","n_dependent_lines":1,"n_total_lines":1208,"dependency_fraction":0.0008278145695364238},"opencell":{"profiled":false,"resolved_as":"","ensg_id":"","cell_line_id":"","localizations":[],"interactors":[],"url":"https://opencell.sf.czbiohub.org/search/CYP11B1","total_profiled":1310},"omim":[{"mim_id":"614409","title":"SPASTIC PARAPLEGIA 46, AUTOSOMAL RECESSIVE; SPG46","url":"https://www.omim.org/entry/614409"},{"mim_id":"613815","title":"CYTOCHROME P450, FAMILY 21, SUBFAMILY A, POLYPEPTIDE 2; CYP21A2","url":"https://www.omim.org/entry/613815"},{"mim_id":"613677","title":"HYPERALDOSTERONISM, FAMILIAL, TYPE III; HALD3","url":"https://www.omim.org/entry/613677"},{"mim_id":"610613","title":"CYTOCHROME P450, SUBFAMILY XIB, POLYPEPTIDE 1; CYP11B1","url":"https://www.omim.org/entry/610613"},{"mim_id":"610600","title":"CORTICOSTERONE METHYLOXIDASE TYPE II DEFICIENCY","url":"https://www.omim.org/entry/610600"}],"hpa":{"profiled":true,"resolved_as":"","reliability":"Approved","locations":[{"location":"Mitochondria","reliability":"Approved"}],"tissue_specificity":"Tissue enriched","tissue_distribution":"Detected in some","driving_tissues":[{"tissue":"adrenal gland","ntpm":3344.5}],"url":"https://www.proteinatlas.org/search/CYP11B1"},"hgnc":{"alias_symbol":["P450C11","FHI","CPN1"],"prev_symbol":["CYP11B"]},"alphafold":{"accession":"P15538","domains":[{"cath_id":"1.10.630.10","chopping":"64-431_441-479_487-502","consensus_level":"medium","plddt":95.2212,"start":64,"end":502}],"viewer_url":"https://alphafold.ebi.ac.uk/entry/P15538","model_url":"https://alphafold.ebi.ac.uk/files/AF-P15538-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-P15538-F1-predicted_aligned_error_v6.png","plddt_mean":90.75},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=CYP11B1","jax_strain_url":"https://www.jax.org/strain/search?query=CYP11B1"},"sequence":{"accession":"P15538","fasta_url":"https://rest.uniprot.org/uniprotkb/P15538.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/P15538/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/P15538"}},"corpus_meta":[{"pmid":"24325867","id":"PMC_24325867","title":"Development of monoclonal antibodies against human CYP11B1 and CYP11B2.","date":"2013","source":"Molecular and cellular endocrinology","url":"https://pubmed.ncbi.nlm.nih.gov/24325867","citation_count":245,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"8247022","id":"PMC_8247022","title":"Activation of CYP11A and CYP11B gene promoters by the steroidogenic cell-specific transcription factor, Ad4BP.","date":"1993","source":"Molecular endocrinology (Baltimore, Md.)","url":"https://pubmed.ncbi.nlm.nih.gov/8247022","citation_count":211,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"3499608","id":"PMC_3499608","title":"Cloning of cDNA encoding steroid 11 beta-hydroxylase (P450c11).","date":"1987","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/3499608","citation_count":207,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"1518866","id":"PMC_1518866","title":"Glucocorticoid-suppressible hyperaldosteronism results from hybrid genes created by unequal crossovers between CYP11B1 and CYP11B2.","date":"1992","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/1518866","citation_count":207,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"2022736","id":"PMC_2022736","title":"A mutation in CYP11B1 (Arg-448----His) associated with steroid 11 beta-hydroxylase deficiency in Jews of Moroccan origin.","date":"1991","source":"The Journal of clinical investigation","url":"https://pubmed.ncbi.nlm.nih.gov/2022736","citation_count":200,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"8506298","id":"PMC_8506298","title":"Mutations in the CYP11B1 gene causing congenital adrenal hyperplasia and hypertension cluster in exons 6, 7, and 8.","date":"1993","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/8506298","citation_count":165,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"9302260","id":"PMC_9302260","title":"CYP11B1 mutations causing non-classic adrenal hyperplasia due to 11 beta-hydroxylase deficiency.","date":"1997","source":"Human molecular genetics","url":"https://pubmed.ncbi.nlm.nih.gov/9302260","citation_count":92,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"24837548","id":"PMC_24837548","title":"Adrenal CYP11B1/2 expression in primary aldosteronism: immunohistochemical analysis using novel monoclonal antibodies.","date":"2014","source":"Molecular and cellular endocrinology","url":"https://pubmed.ncbi.nlm.nih.gov/24837548","citation_count":89,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"9814482","id":"PMC_9814482","title":"Recombinant CYP11B genes encode enzymes that can catalyze conversion of 11-deoxycortisol to cortisol, 18-hydroxycortisol, and 18-oxocortisol.","date":"1998","source":"The Journal of clinical endocrinology and metabolism","url":"https://pubmed.ncbi.nlm.nih.gov/9814482","citation_count":86,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"20089618","id":"PMC_20089618","title":"Functional consequences of seven novel mutations in the CYP11B1 gene: four mutations associated with nonclassic and three mutations causing classic 11{beta}-hydroxylase deficiency.","date":"2010","source":"The Journal of clinical endocrinology and metabolism","url":"https://pubmed.ncbi.nlm.nih.gov/20089618","citation_count":75,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"2052554","id":"PMC_2052554","title":"Zone-specific regulation of two messenger RNAs for P450c11 in the adrenals of pregnant and nonpregnant rats.","date":"1991","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/2052554","citation_count":70,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"7588408","id":"PMC_7588408","title":"Cloning of CYP11B1 and CYP11B2 from normal human adrenal and their functional expression in COS-7 and V79 Chinese hamster cells.","date":"1995","source":"Endocrine research","url":"https://pubmed.ncbi.nlm.nih.gov/7588408","citation_count":67,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"12457455","id":"PMC_12457455","title":"Quantitative assessment of CYP11B1 and CYP11B2 expression in aldosterone-producing adenomas.","date":"2002","source":"European journal of endocrinology","url":"https://pubmed.ncbi.nlm.nih.gov/12457455","citation_count":59,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"24900247","id":"PMC_24900247","title":"First Selective CYP11B1 Inhibitors for the Treatment of Cortisol-Dependent Diseases.","date":"2010","source":"ACS medicinal chemistry letters","url":"https://pubmed.ncbi.nlm.nih.gov/24900247","citation_count":58,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"25465475","id":"PMC_25465475","title":"The CYP11B subfamily.","date":"2014","source":"The Journal of steroid biochemistry and molecular biology","url":"https://pubmed.ncbi.nlm.nih.gov/25465475","citation_count":57,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"8473352","id":"PMC_8473352","title":"Isolation and characterization of rat CYP11B genes involved in late steps of mineralo- and glucocorticoid syntheses.","date":"1993","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/8473352","citation_count":56,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"7798178","id":"PMC_7798178","title":"Contribution of Ad4BP, a steroidogenic cell-specific transcription factor, to regulation of the human CYP11A and bovine CYP11B genes through their distal promoters.","date":"1994","source":"Journal of biochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/7798178","citation_count":55,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"1430088","id":"PMC_1430088","title":"Frame shift by insertion of 2 basepairs in codon 394 of CYP11B1 causes congenital adrenal hyperplasia due to steroid 11 beta-hydroxylase deficiency.","date":"1992","source":"The Journal of clinical endocrinology and metabolism","url":"https://pubmed.ncbi.nlm.nih.gov/1430088","citation_count":53,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"7829497","id":"PMC_7829497","title":"P450c11B3 mRNA, transcribed from a third P450c11 gene, is expressed in a tissue-specific, developmentally, and hormonally regulated fashion in the rodent adrenal and encodes a protein with both 11-hydroxylase and 18-hydroxylase activities.","date":"1995","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/7829497","citation_count":51,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"8468320","id":"PMC_8468320","title":"Three forms of rat CYP11B genes: 11 beta-hydroxylase gene, aldosterone synthase gene, and a novel gene.","date":"1993","source":"Journal of biochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/8468320","citation_count":49,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"12682779","id":"PMC_12682779","title":"Defining the blood pressure QTL on chromosome 7 in Dahl rats by a 177-kb congenic segment containing Cyp11b1.","date":"2003","source":"Mammalian genome : official journal of the International Mammalian Genome Society","url":"https://pubmed.ncbi.nlm.nih.gov/12682779","citation_count":49,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"9546661","id":"PMC_9546661","title":"Conferring aldosterone synthesis to human CYP11B1 by replacing key amino acid residues with CYP11B2-specific ones.","date":"1998","source":"European journal of biochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/9546661","citation_count":48,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"17179535","id":"PMC_17179535","title":"Joint analysis of the influence of CYP11B1 and DGAT1 genetic variation on milk production, somatic cell score, conformation, reproduction, and productive lifespan in German Holstein cattle.","date":"2007","source":"Journal of animal science","url":"https://pubmed.ncbi.nlm.nih.gov/17179535","citation_count":46,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"15755848","id":"PMC_15755848","title":"Congenital adrenal hyperplasia due to 11-hydroxylase deficiency: functional characterization of two novel point mutations and a three-base pair deletion in the CYP11B1 gene.","date":"2005","source":"The Journal of clinical endocrinology and metabolism","url":"https://pubmed.ncbi.nlm.nih.gov/15755848","citation_count":45,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"11095433","id":"PMC_11095433","title":"Bilateral laparoscopic adrenalectomy for congenital adrenal hyperplasia with severe hypertension, resulting from two novel mutations in splice donor sites of CYP11B1.","date":"2000","source":"The Journal of clinical endocrinology and metabolism","url":"https://pubmed.ncbi.nlm.nih.gov/11095433","citation_count":44,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"16396990","id":"PMC_16396990","title":"Mechanistic study of polychlorinated biphenyl 126-induced CYP11B1 and CYP11B2 up-regulation.","date":"2006","source":"Endocrinology","url":"https://pubmed.ncbi.nlm.nih.gov/16396990","citation_count":42,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"23869452","id":"PMC_23869452","title":"Cushing's syndrome: development of highly potent and selective CYP11B1 inhibitors of the (pyridylmethyl)pyridine type.","date":"2013","source":"Journal of medicinal chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/23869452","citation_count":42,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"20684610","id":"PMC_20684610","title":"Replacement of imidazolyl by pyridyl in biphenylmethylenes results in selective CYP17 and dual CYP17/CYP11B1 inhibitors for the treatment of prostate cancer.","date":"2010","source":"Journal of medicinal chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/20684610","citation_count":42,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"16179417","id":"PMC_16179417","title":"The aldosterone synthase (CYP11B2) and 11beta-hydroxylase (CYP11B1) genes are not expressed in the rat heart.","date":"2005","source":"Endocrinology","url":"https://pubmed.ncbi.nlm.nih.gov/16179417","citation_count":41,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"11443188","id":"PMC_11443188","title":"Deletion hybrid genes, due to unequal crossing over between CYP11B1 (11beta-hydroxylase) and CYP11B2(aldosterone synthase) cause steroid 11beta-hydroxylase deficiency and congenital adrenal hyperplasia.","date":"2001","source":"The Journal of clinical endocrinology and metabolism","url":"https://pubmed.ncbi.nlm.nih.gov/11443188","citation_count":41,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"24022297","id":"PMC_24022297","title":"Congenital adrenal hyperplasia due to 11-beta-hydroxylase deficiency: functional consequences of four CYP11B1 mutations.","date":"2013","source":"European journal of human genetics : EJHG","url":"https://pubmed.ncbi.nlm.nih.gov/24022297","citation_count":40,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"24900631","id":"PMC_24900631","title":"Discovery and in Vivo Evaluation of Potent Dual CYP11B2 (Aldosterone Synthase) and CYP11B1 Inhibitors.","date":"2013","source":"ACS medicinal chemistry letters","url":"https://pubmed.ncbi.nlm.nih.gov/24900631","citation_count":39,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"7673111","id":"PMC_7673111","title":"Novel involvement of a mitochondrial steroid hydroxylase (P450c11) in xenobiotic metabolism.","date":"1995","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/7673111","citation_count":39,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"19414808","id":"PMC_19414808","title":"Targeted disruption of the gene encoding the murine small subunit of carboxypeptidase N (CPN1) causes susceptibility to C5a anaphylatoxin-mediated shock.","date":"2009","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/19414808","citation_count":38,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"11459837","id":"PMC_11459837","title":"The interaction of bovine adrenodoxin with CYP11A1 (cytochrome P450scc) and CYP11B1 (cytochrome P45011beta ). Acceleration of reduction and substrate conversion by site-directed mutagenesis of adrenodoxin.","date":"2001","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/11459837","citation_count":38,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"11196473","id":"PMC_11196473","title":"Regulation of human CYP11B2 and CYP11B1: comparing the role of the common CRE/Ad1 element.","date":"2000","source":"Endocrine research","url":"https://pubmed.ncbi.nlm.nih.gov/11196473","citation_count":37,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"7903314","id":"PMC_7903314","title":"A nonsense mutation (TGG [Trp116]-->TAG [Stop]) in CYP11B1 causes steroid 11 beta-hydroxylase deficiency.","date":"1993","source":"The Journal of clinical endocrinology and metabolism","url":"https://pubmed.ncbi.nlm.nih.gov/7903314","citation_count":37,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"8964882","id":"PMC_8964882","title":"Single strand conformation polymorphism (SSCP) analysis for the detection of mutations in the CYP11B1 gene.","date":"1996","source":"The Journal of clinical endocrinology and metabolism","url":"https://pubmed.ncbi.nlm.nih.gov/8964882","citation_count":36,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"19029289","id":"PMC_19029289","title":"Cyp11b1 null mouse, a model of congenital adrenal hyperplasia.","date":"2008","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/19029289","citation_count":36,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"15134825","id":"PMC_15134825","title":"Development of test systems for the discovery of selective human aldosterone synthase (CYP11B2) and 11beta-hydroxylase (CYP11B1) inhibitors. Discovery of a new lead compound for the therapy of congestive heart failure, myocardial fibrosis and hypertension.","date":"2004","source":"Molecular and cellular endocrinology","url":"https://pubmed.ncbi.nlm.nih.gov/15134825","citation_count":35,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"12153581","id":"PMC_12153581","title":"Analyses of the CYP11B gene family in the guinea pig suggest the existence of a primordial CYP11B gene with aldosterone synthase activity.","date":"2002","source":"European journal of biochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/12153581","citation_count":35,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"12525251","id":"PMC_12525251","title":"Transforming growth factor beta1 inhibits aldosterone and cortisol production in the human adrenocortical cell line NCI-H295R through inhibition of CYP11B1 and CYP11B2 expression.","date":"2003","source":"The Journal of endocrinology","url":"https://pubmed.ncbi.nlm.nih.gov/12525251","citation_count":35,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"17935813","id":"PMC_17935813","title":"Coexpression of redox partners increases the hydrocortisone (cortisol) production efficiency in CYP11B1 expressing fission yeast Schizosaccharomyces pombe.","date":"2007","source":"Journal of biotechnology","url":"https://pubmed.ncbi.nlm.nih.gov/17935813","citation_count":33,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"7565753","id":"PMC_7565753","title":"Involvement of an AP-1 complex in zone-specific expression of the CYP11B1 gene in the rat adrenal cortex.","date":"1995","source":"Molecular and cellular biology","url":"https://pubmed.ncbi.nlm.nih.gov/7565753","citation_count":31,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"19622340","id":"PMC_19622340","title":"Coexpression of CYP11B2 or CYP11B1 with adrenodoxin and adrenodoxin reductase for assessing the potency and selectivity of aldosterone synthase inhibitors.","date":"2009","source":"Analytical biochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/19622340","citation_count":30,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"36982850","id":"PMC_36982850","title":"Molecular and Epigenetic Control of Aldosterone Synthase, CYP11B2 and 11-Hydroxylase, CYP11B1.","date":"2023","source":"International journal of molecular sciences","url":"https://pubmed.ncbi.nlm.nih.gov/36982850","citation_count":29,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"17726333","id":"PMC_17726333","title":"Successful pregnancy in a patient with severe 11-beta-hydroxylase deficiency and novel mutations in CYP11B1 gene.","date":"2007","source":"Hormone research","url":"https://pubmed.ncbi.nlm.nih.gov/17726333","citation_count":29,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"17124386","id":"PMC_17124386","title":"Cosegregation of a novel homozygous CYP11B1 mutation with the phenotype of non-classical congenital adrenal hyperplasia in a consanguineous family.","date":"2006","source":"Hormone research","url":"https://pubmed.ncbi.nlm.nih.gov/17124386","citation_count":29,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"24900349","id":"PMC_24900349","title":"Optimization of the First Selective Steroid-11β-hydroxylase (CYP11B1) Inhibitors for the Treatment of Cortisol Dependent Diseases.","date":"2011","source":"ACS medicinal chemistry letters","url":"https://pubmed.ncbi.nlm.nih.gov/24900349","citation_count":29,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"24768260","id":"PMC_24768260","title":"Regulation of CYP11B1 and CYP11B2 steroidogenic genes by hypoxia-inducible miR-10b in H295R cells.","date":"2014","source":"Marine pollution bulletin","url":"https://pubmed.ncbi.nlm.nih.gov/24768260","citation_count":28,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"9746364","id":"PMC_9746364","title":"Adrenocorticotropic hormone stimulates CYP11B1 gene transcription through a mechanism involving AP-1 factors.","date":"1998","source":"European journal of biochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/9746364","citation_count":28,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"9874258","id":"PMC_9874258","title":"Structure/function relationship of CYP11B1 associated with Dahl's salt-resistant rats--expression of rat CYP11B1 and CYP11B2 in Escherichia coli.","date":"1998","source":"European journal of biochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/9874258","citation_count":28,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"25609776","id":"PMC_25609776","title":"Abundance of DLK1, differential expression of CYP11B1, CYP21A2 and MC2R, and lack of INSL3 distinguish testicular adrenal rest tumours from Leydig cell tumours.","date":"2015","source":"European journal of endocrinology","url":"https://pubmed.ncbi.nlm.nih.gov/25609776","citation_count":28,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"17890294","id":"PMC_17890294","title":"Expression of Cyp21a1 and Cyp11b1 in the fetal mouse testis.","date":"2007","source":"Reproduction (Cambridge, England)","url":"https://pubmed.ncbi.nlm.nih.gov/17890294","citation_count":27,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"11600544","id":"PMC_11600544","title":"Genetic study of patients with dexamethasone-suppressible aldosteronism without the chimeric CYP11B1/CYP11B2 gene.","date":"2001","source":"The Journal of clinical endocrinology and metabolism","url":"https://pubmed.ncbi.nlm.nih.gov/11600544","citation_count":27,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"16030166","id":"PMC_16030166","title":"Mutations in CYP11B1 and congenital adrenal hyperplasia in Moroccan Jews.","date":"2005","source":"The Journal of clinical endocrinology and metabolism","url":"https://pubmed.ncbi.nlm.nih.gov/16030166","citation_count":27,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"1336011","id":"PMC_1336011","title":"Cooperative transcription activation between Ad1, a CRE-like element, and other elements in the CYP11B gene promoter.","date":"1992","source":"Journal of biochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/1336011","citation_count":26,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"12966519","id":"PMC_12966519","title":"Mutations in CYP11B1 gene: phenotype-genotype correlations.","date":"2003","source":"American journal of medical genetics. Part A","url":"https://pubmed.ncbi.nlm.nih.gov/12966519","citation_count":25,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"22964742","id":"PMC_22964742","title":"A prevalent and three novel mutations in CYP11B1 gene identified in Chinese patients with 11-beta hydroxylase deficiency.","date":"2012","source":"The Journal of steroid biochemistry and molecular biology","url":"https://pubmed.ncbi.nlm.nih.gov/22964742","citation_count":25,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"7889175","id":"PMC_7889175","title":"Missense mutation in CYP11B1 (CGA[Arg-384]-->GGA[Gly]) causes steroid 11 beta-hydroxylase deficiency.","date":"1995","source":"European journal of endocrinology","url":"https://pubmed.ncbi.nlm.nih.gov/7889175","citation_count":25,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"23150505","id":"PMC_23150505","title":"Common polymorphisms in the CYP11B1 and CYP11B2 genes: evidence for a digenic influence on hypertension.","date":"2012","source":"Hypertension (Dallas, Tex. : 1979)","url":"https://pubmed.ncbi.nlm.nih.gov/23150505","citation_count":25,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"24536089","id":"PMC_24536089","title":"Characterisation of three novel CYP11B1 mutations in classic and non-classic 11β-hydroxylase deficiency.","date":"2014","source":"European journal of endocrinology","url":"https://pubmed.ncbi.nlm.nih.gov/24536089","citation_count":24,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"16984984","id":"PMC_16984984","title":"Association between aldosterone production and variation in the 11beta-hydroxylase (CYP11B1) gene.","date":"2006","source":"The Journal of clinical endocrinology and metabolism","url":"https://pubmed.ncbi.nlm.nih.gov/16984984","citation_count":24,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"25880059","id":"PMC_25880059","title":"A recombinant CYP11B1 dependent Escherichia coli biocatalyst for selective cortisol production and optimization towards a preparative scale.","date":"2015","source":"Microbial cell factories","url":"https://pubmed.ncbi.nlm.nih.gov/25880059","citation_count":24,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"8645611","id":"PMC_8645611","title":"The hamster adrenal cytochrome P450C11 has equipotent 11beta-hydroxylase and 19-hydroxylase activities, but no aldosterone synthase activity.","date":"1996","source":"The Journal of steroid biochemistry and molecular biology","url":"https://pubmed.ncbi.nlm.nih.gov/8645611","citation_count":23,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"26956189","id":"PMC_26956189","title":"Novel and prevalent CYP11B1 gene mutations in Turkish patients with 11-β hydroxylase deficiency.","date":"2016","source":"The Journal of steroid biochemistry and molecular biology","url":"https://pubmed.ncbi.nlm.nih.gov/26956189","citation_count":23,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"28894201","id":"PMC_28894201","title":"Cortisol overproduction results from DNA methylation of CYP11B1 in hypercortisolemia.","date":"2017","source":"Scientific reports","url":"https://pubmed.ncbi.nlm.nih.gov/28894201","citation_count":23,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"15985365","id":"PMC_15985365","title":"The adrenocortical tumor cell line NCI-H295R as an in vitro screening system for the evaluation of CYP11B2 (aldosterone synthase) and CYP11B1 (steroid-11beta-hydroxylase) inhibitors.","date":"2005","source":"The Journal of steroid biochemistry and molecular biology","url":"https://pubmed.ncbi.nlm.nih.gov/15985365","citation_count":23,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"19567537","id":"PMC_19567537","title":"Novel mutations in CYP11B1 gene leading to 11 beta-hydroxylase deficiency in Brazilian patients.","date":"2009","source":"The Journal of clinical endocrinology and metabolism","url":"https://pubmed.ncbi.nlm.nih.gov/19567537","citation_count":23,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"7588406","id":"PMC_7588406","title":"Human adrenal CYP11B1: localization by in situ-hybridization and functional expression in cell cultures.","date":"1995","source":"Endocrine research","url":"https://pubmed.ncbi.nlm.nih.gov/7588406","citation_count":22,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"10411633","id":"PMC_10411633","title":"Interaction of CYP11B1 (cytochrome P-45011 beta) with CYP11A1 (cytochrome P-450scc) in COS-1 cells.","date":"1999","source":"European journal of biochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/10411633","citation_count":21,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"19844114","id":"PMC_19844114","title":"Congenital adrenal hyperplasia due to 11-hydroxylase deficiency--insights from two novel CYP11B1 mutations (p.M92X, p.R453Q).","date":"2009","source":"Hormone research","url":"https://pubmed.ncbi.nlm.nih.gov/19844114","citation_count":21,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"15507509","id":"PMC_15507509","title":"CYP11B2-CYP11B1 haplotypes associated with decreased 11 beta-hydroxylase activity.","date":"2004","source":"The Journal of clinical endocrinology and metabolism","url":"https://pubmed.ncbi.nlm.nih.gov/15507509","citation_count":21,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"28069904","id":"PMC_28069904","title":"Detection and activity of 11 beta hydroxylase (CYP11B1) in the bovine ovary.","date":"2017","source":"Reproduction (Cambridge, England)","url":"https://pubmed.ncbi.nlm.nih.gov/28069904","citation_count":20,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"10566677","id":"PMC_10566677","title":"Mutations in CYP11B1 gene converting 11beta-hydroxylase into an aldosterone-producing enzyme are not present in aldosterone-producing adenomas.","date":"1999","source":"The Journal of clinical endocrinology and metabolism","url":"https://pubmed.ncbi.nlm.nih.gov/10566677","citation_count":20,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"25100385","id":"PMC_25100385","title":"Divergent gender identity in three siblings with 46XX karyotype and severely virilizing congenital adrenal hyperplasia caused by a novel CYP11B1 mutation.","date":"2014","source":"Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists","url":"https://pubmed.ncbi.nlm.nih.gov/25100385","citation_count":20,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"29626607","id":"PMC_29626607","title":"Prevalence, clinical characteristics and long-term outcomes of classical 11 β-hydroxylase deficiency (11BOHD) in Turkish population and novel mutations in CYP11B1 gene.","date":"2018","source":"The Journal of steroid biochemistry and molecular biology","url":"https://pubmed.ncbi.nlm.nih.gov/29626607","citation_count":20,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"12560874","id":"PMC_12560874","title":"DNA polymorphism and mutations in CPN1, including the genomic basis of carboxypeptidase N deficiency.","date":"2003","source":"Journal of human genetics","url":"https://pubmed.ncbi.nlm.nih.gov/12560874","citation_count":19,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"8969896","id":"PMC_8969896","title":"Changed ratios of glucocorticoids/mineralocorticoids caused by point mutations in the putative I-helix regions of CYP11B1 and CYP11B2.","date":"1996","source":"Endocrine research","url":"https://pubmed.ncbi.nlm.nih.gov/8969896","citation_count":19,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"16024935","id":"PMC_16024935","title":"Steroid 11-beta-hydroxylase deficiency caused by compound heterozygosity for a novel mutation, p.G314R, in one CYP11B1 allele, and a chimeric CYP11B2/CYP11B1 in the other allele.","date":"2005","source":"Hormone research","url":"https://pubmed.ncbi.nlm.nih.gov/16024935","citation_count":19,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"26476331","id":"PMC_26476331","title":"Phenotypic, metabolic, and molecular genetic characterization of six patients with congenital adrenal hyperplasia caused by novel mutations in the CYP11B1 gene.","date":"2015","source":"The Journal of steroid biochemistry and molecular biology","url":"https://pubmed.ncbi.nlm.nih.gov/26476331","citation_count":18,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"20523022","id":"PMC_20523022","title":"Three novel CYP11B1 mutations in congenital adrenal hyperplasia due to steroid 11Beta-hydroxylase deficiency in a moroccan population.","date":"2010","source":"Hormone research in paediatrics","url":"https://pubmed.ncbi.nlm.nih.gov/20523022","citation_count":18,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"22210247","id":"PMC_22210247","title":"Two novel CYP11B1 mutations in congenital adrenal hyperplasia due to steroid 11β hydroxylase deficiency in a Tunisian family.","date":"2011","source":"General and comparative endocrinology","url":"https://pubmed.ncbi.nlm.nih.gov/22210247","citation_count":18,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"8784078","id":"PMC_8784078","title":"The human genome contains only two CYP11B (P450c11) genes.","date":"1996","source":"The Journal of clinical endocrinology and metabolism","url":"https://pubmed.ncbi.nlm.nih.gov/8784078","citation_count":15,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"9408886","id":"PMC_9408886","title":"Expression of 11 beta-hydroxylase (CYP11B1) and aldosterone synthase (CYP11B2) in the human fetal adrenal.","date":"1997","source":"Journal of the Society for Gynecologic Investigation","url":"https://pubmed.ncbi.nlm.nih.gov/9408886","citation_count":15,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"15324322","id":"PMC_15324322","title":"Neonatal salt-wasting and 11 beta-hydroxylase deficiency in a child carrying a homozygous deletion hybrid CYP11B2 (aldosterone synthase)-CYP11B1 (11 beta-hydroxylase).","date":"2004","source":"Clinical genetics","url":"https://pubmed.ncbi.nlm.nih.gov/15324322","citation_count":15,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"34743356","id":"PMC_34743356","title":"Expression of CYP11B1 and CYP11B2 in adrenal adenoma correlates with clinical characteristics of primary aldosteronism.","date":"2021","source":"Clinical endocrinology","url":"https://pubmed.ncbi.nlm.nih.gov/34743356","citation_count":14,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"26066897","id":"PMC_26066897","title":"Chimeric CYP11B2/CYP11B1 causing 11β-hydroxylase deficiency in Chinese patients with congenital adrenal hyperplasia.","date":"2015","source":"Steroids","url":"https://pubmed.ncbi.nlm.nih.gov/26066897","citation_count":14,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"17121536","id":"PMC_17121536","title":"Functional effects of genetic variants in the 11beta-hydroxylase (CYP11B1) gene.","date":"2006","source":"Clinical endocrinology","url":"https://pubmed.ncbi.nlm.nih.gov/17121536","citation_count":14,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"18663314","id":"PMC_18663314","title":"A homozygous L299P mutation in the CYP11B1 gene leads to complete virilization in 46,XX individuals with 11-beta-hydroxylase deficiency.","date":"2008","source":"Hormone research","url":"https://pubmed.ncbi.nlm.nih.gov/18663314","citation_count":14,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"26303746","id":"PMC_26303746","title":"Development of CYP11B1 and CYP11B2 assays utilizing homogenates of adrenal glands: Utility of monkey as a surrogate for human.","date":"2015","source":"The Journal of steroid biochemistry and molecular biology","url":"https://pubmed.ncbi.nlm.nih.gov/26303746","citation_count":14,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"24621779","id":"PMC_24621779","title":"Uniparental disomy of chromosome 8 leading to homozygosity of a CYP11B1 mutation in a patient with congenital adrenal hyperplasia: implication for a rare etiology of an autosomal recessive disorder.","date":"2014","source":"Endocrine journal","url":"https://pubmed.ncbi.nlm.nih.gov/24621779","citation_count":14,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"7488170","id":"PMC_7488170","title":"Classic steroid 11 beta-hydroxylase deficiency caused by a C-->G transversion in exon 7 of CYP11B1.","date":"1995","source":"Biochemical and biophysical research communications","url":"https://pubmed.ncbi.nlm.nih.gov/7488170","citation_count":14,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"21848792","id":"PMC_21848792","title":"Increased expression of CYP17 and CYP11B1 in subclinical Cushing's syndrome due to adrenal adenomas.","date":"2011","source":"International journal of urology : official journal of the Japanese Urological Association","url":"https://pubmed.ncbi.nlm.nih.gov/21848792","citation_count":13,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"22172629","id":"PMC_22172629","title":"Flavonoids exhibit diverse effects on CYP11B1 expression and cortisol synthesis.","date":"2011","source":"Toxicology and applied pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/22172629","citation_count":13,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"22079243","id":"PMC_22079243","title":"Regulation of human CYP11B1 and CYP11B2 promoters by transposable elements and conserved cis elements.","date":"2011","source":"Steroids","url":"https://pubmed.ncbi.nlm.nih.gov/22079243","citation_count":12,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"7779756","id":"PMC_7779756","title":"Stable expression of rat cytochrome P450 11 beta-hydroxylase (CYP11B1) and aldosterone synthase (CYP11B2) in MA-10 cells.","date":"1995","source":"The Journal of steroid biochemistry and molecular biology","url":"https://pubmed.ncbi.nlm.nih.gov/7779756","citation_count":12,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"20339375","id":"PMC_20339375","title":"Polymorphisms in CYP11B2 and CYP11B1 genes associated with primary hyperaldosteronism.","date":"2010","source":"Hypertension research : official journal of the Japanese Society of Hypertension","url":"https://pubmed.ncbi.nlm.nih.gov/20339375","citation_count":12,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"23345044","id":"PMC_23345044","title":"Two novel mutations in CYP11B1 and modeling the consequent alterations of the translated protein in classic congenital adrenal hyperplasia patients.","date":"2013","source":"Endocrine","url":"https://pubmed.ncbi.nlm.nih.gov/23345044","citation_count":12,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"20024693","id":"PMC_20024693","title":"Steroid 11-beta hydroxylase deficiency caused by compound heterozygosity for a novel mutation in intron 7 (IVS 7 DS+4A to G) in one CYP11B1 allele and R448H in exon 8 in the other.","date":"2009","source":"European journal of pediatrics","url":"https://pubmed.ncbi.nlm.nih.gov/20024693","citation_count":12,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"12477932","id":"PMC_12477932","title":"Generation and initial analysis of more than 15,000 full-length human and mouse cDNA sequences.","date":"2002","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/12477932","citation_count":1479,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"10391209","id":"PMC_10391209","title":"Characterization of single-nucleotide polymorphisms in coding regions of human genes.","date":"1999","source":"Nature genetics","url":"https://pubmed.ncbi.nlm.nih.gov/10391209","citation_count":1381,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"15583024","id":"PMC_15583024","title":"Overview of steroidogenic enzymes in the pathway from cholesterol to active steroid hormones.","date":"2004","source":"Endocrine reviews","url":"https://pubmed.ncbi.nlm.nih.gov/15583024","citation_count":1274,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"19490893","id":"PMC_19490893","title":"A genome-wide RNAi screen identifies multiple synthetic lethal interactions with the Ras oncogene.","date":"2009","source":"Cell","url":"https://pubmed.ncbi.nlm.nih.gov/19490893","citation_count":843,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"10391210","id":"PMC_10391210","title":"Patterns of single-nucleotide polymorphisms in candidate genes for blood-pressure homeostasis.","date":"1999","source":"Nature genetics","url":"https://pubmed.ncbi.nlm.nih.gov/10391210","citation_count":769,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"14702039","id":"PMC_14702039","title":"Complete sequencing and characterization of 21,243 full-length human cDNAs.","date":"2003","source":"Nature genetics","url":"https://pubmed.ncbi.nlm.nih.gov/14702039","citation_count":754,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"15128046","id":"PMC_15128046","title":"Comparison of cytochrome P450 (CYP) genes from the mouse and human genomes, including nomenclature recommendations for genes, pseudogenes and alternative-splice variants.","date":"2004","source":"Pharmacogenetics","url":"https://pubmed.ncbi.nlm.nih.gov/15128046","citation_count":729,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"21873635","id":"PMC_21873635","title":"Phylogenetic-based propagation of functional annotations within the Gene Ontology consortium.","date":"2011","source":"Briefings in bioinformatics","url":"https://pubmed.ncbi.nlm.nih.gov/21873635","citation_count":656,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"2592361","id":"PMC_2592361","title":"Characterization of two genes encoding human steroid 11 beta-hydroxylase (P-450(11) beta).","date":"1989","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/2592361","citation_count":436,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"1303253","id":"PMC_1303253","title":"Hereditary hypertension caused by chimaeric gene duplications and ectopic expression of aldosterone synthase.","date":"1992","source":"Nature genetics","url":"https://pubmed.ncbi.nlm.nih.gov/1303253","citation_count":273,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"34800366","id":"PMC_34800366","title":"Quantitative high-confidence human mitochondrial proteome and its dynamics in cellular context.","date":"2021","source":"Cell metabolism","url":"https://pubmed.ncbi.nlm.nih.gov/34800366","citation_count":239,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"19598235","id":"PMC_19598235","title":"Genes related to sex steroids, neural growth, and social-emotional behavior are associated with autistic traits, empathy, and Asperger syndrome.","date":"2009","source":"Autism research : official journal of the International Society for Autism Research","url":"https://pubmed.ncbi.nlm.nih.gov/19598235","citation_count":223,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"1741400","id":"PMC_1741400","title":"Role of steroid 11 beta-hydroxylase and steroid 18-hydroxylase in the biosynthesis of glucocorticoids and mineralocorticoids in humans.","date":"1992","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/1741400","citation_count":213,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"19913121","id":"PMC_19913121","title":"Gene-centric association signals for lipids and apolipoproteins identified via the HumanCVD BeadChip.","date":"2009","source":"American journal of human genetics","url":"https://pubmed.ncbi.nlm.nih.gov/19913121","citation_count":164,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"2256920","id":"PMC_2256920","title":"Cloning and expression of a cDNA for human cytochrome P-450aldo as related to primary aldosteronism.","date":"1990","source":"Biochemical and biophysical research communications","url":"https://pubmed.ncbi.nlm.nih.gov/2256920","citation_count":150,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"11932209","id":"PMC_11932209","title":"Differential regulation of aldosterone synthase and 11beta-hydroxylase transcription by steroidogenic factor-1.","date":"2002","source":"Journal of molecular endocrinology","url":"https://pubmed.ncbi.nlm.nih.gov/11932209","citation_count":126,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"2401360","id":"PMC_2401360","title":"Cloning of cDNA and genomic DNA for human cytochrome P-45011 beta.","date":"1990","source":"FEBS letters","url":"https://pubmed.ncbi.nlm.nih.gov/2401360","citation_count":104,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"18294861","id":"PMC_18294861","title":"Steroid 11beta- hydroxylase deficiency congenital adrenal hyperplasia.","date":"2008","source":"Trends in endocrinology and metabolism: TEM","url":"https://pubmed.ncbi.nlm.nih.gov/18294861","citation_count":99,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"28228528","id":"PMC_28228528","title":"Clinical, genetic, and structural basis of congenital adrenal hyperplasia due to 11β-hydroxylase deficiency.","date":"2017","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/28228528","citation_count":93,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"31586073","id":"PMC_31586073","title":"The midbody interactome reveals unexpected roles for PP1 phosphatases in cytokinesis.","date":"2019","source":"Nature communications","url":"https://pubmed.ncbi.nlm.nih.gov/31586073","citation_count":74,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"18636124","id":"PMC_18636124","title":"Polymorphisms in the estrogen receptor 1 and vitamin C and matrix metalloproteinase gene families are associated with susceptibility to lymphoma.","date":"2008","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/18636124","citation_count":70,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"18397978","id":"PMC_18397978","title":"[123 I]Iodometomidate for molecular imaging of adrenocortical cytochrome P450 family 11B enzymes.","date":"2008","source":"The Journal of clinical endocrinology and metabolism","url":"https://pubmed.ncbi.nlm.nih.gov/18397978","citation_count":69,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"12452430","id":"PMC_12452430","title":"The human steroid hydroxylases CYP1B1 and CYP11B2.","date":"2002","source":"Biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/12452430","citation_count":68,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"15026188","id":"PMC_15026188","title":"Modulation of aldosterone and cortisol synthesis on the molecular level.","date":"2004","source":"Molecular and cellular endocrinology","url":"https://pubmed.ncbi.nlm.nih.gov/15026188","citation_count":66,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"11549691","id":"PMC_11549691","title":"Unequal crossing-over between aldosterone synthase and 11beta-hydroxylase genes causes congenital adrenal hyperplasia.","date":"2001","source":"The Journal of clinical endocrinology and metabolism","url":"https://pubmed.ncbi.nlm.nih.gov/11549691","citation_count":52,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"19453261","id":"PMC_19453261","title":"High-density association study of 383 candidate genes for volumetric BMD at the femoral neck and lumbar spine among older men.","date":"2009","source":"Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research","url":"https://pubmed.ncbi.nlm.nih.gov/19453261","citation_count":52,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"18974272","id":"PMC_18974272","title":"Differential effects of high and low steroidogenic factor-1 expression on CYP11B2 expression and aldosterone production in adrenocortical cells.","date":"2008","source":"Endocrinology","url":"https://pubmed.ncbi.nlm.nih.gov/18974272","citation_count":50,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"19336370","id":"PMC_19336370","title":"Determination of genetic predisposition to patent ductus arteriosus in preterm infants.","date":"2009","source":"Pediatrics","url":"https://pubmed.ncbi.nlm.nih.gov/19336370","citation_count":48,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"18215163","id":"PMC_18215163","title":"Purification and functional characterization of human 11beta hydroxylase expressed in Escherichia coli.","date":"2008","source":"The FEBS journal","url":"https://pubmed.ncbi.nlm.nih.gov/18215163","citation_count":43,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"20486282","id":"PMC_20486282","title":"Genetic variants in the renin-angiotensin-aldosterone system and salt sensitivity of blood pressure.","date":"2010","source":"Journal of hypertension","url":"https://pubmed.ncbi.nlm.nih.gov/20486282","citation_count":43,"is_preprint":false,"source_track":"gene2pubmed"}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":53705,"output_tokens":7898,"usd":0.139792},"stage2":{"model":"claude-opus-4-6","input_tokens":11768,"output_tokens":3154,"usd":0.206535},"total_usd":0.716998,"stage1_batch_id":"msgbatch_011kfMfE81o6CTcyhVUqumuW","stage2_batch_id":"msgbatch_01DTputS6WNkH745x1nVSoBo","note":"batch pricing = 50% of standard","round2_stage1":{"model":"claude-sonnet-4-6","input_tokens":68424,"output_tokens":8795,"usd":0.168599},"round2_rules_fired":"R2","round2_stage2":{"model":"claude-opus-4-6","input_tokens":13008,"output_tokens":2787,"usd":0.202072}},"stage1_raw":"```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 1987,\n      \"finding\": \"CYP11B1 encodes a 479-amino acid mature protein (plus 24-residue mitochondrial signal sequence) with 11β-hydroxylase activity, responsible for converting 11-deoxycortisol to cortisol; the gene was cloned from bovine and human adrenal cDNA libraries and localized to chromosome 8q.\",\n      \"method\": \"cDNA cloning, sequence analysis, in situ hybridization to metaphase chromosomes, somatic cell hybrid panel mapping\",\n      \"journal\": \"Proceedings of the National Academy of Sciences of the United States of America\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — original cloning with sequence and chromosomal localization, foundational paper with 207 citations\",\n      \"pmids\": [\"3499608\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1991,\n      \"finding\": \"A missense mutation Arg-448→His in the heme-binding domain of CYP11B1 abolishes 11β-hydroxylase activity; Arg-448 is conserved in every known eukaryotic P450 and is required for enzymatic function.\",\n      \"method\": \"PCR-selective amplification of CYP11B1, sequencing, family segregation analysis; enzymatic activity inferred from patient phenotype\",\n      \"journal\": \"The Journal of clinical investigation\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — mutation in conserved heme-coordinating residue with strong phenotypic and segregation evidence, 200 citations\",\n      \"pmids\": [\"2022736\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1992,\n      \"finding\": \"Glucocorticoid-suppressible hyperaldosteronism (GSH) is caused by unequal meiotic crossing-over producing a hybrid gene with the 5′ regulatory and coding regions of CYP11B1 (conferring ACTH-regulated expression) fused to 3′ coding regions of CYP11B2 (conferring aldosterone synthase activity); hybrid cDNAs containing up to the first three exons of CYP11B1 supported aldosterone synthesis at near-normal CYP11B2 levels, whereas hybrids with five or more CYP11B1 exons could not produce detectable aldosterone.\",\n      \"method\": \"Southern blotting, transfection of hybrid cDNAs into cells, steroid product measurement\",\n      \"journal\": \"Proceedings of the National Academy of Sciences of the United States of America\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 — direct transfection assay with hybrid cDNA constructs demonstrating enzymatic activity determinants, 207 citations\",\n      \"pmids\": [\"1518866\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1992,\n      \"finding\": \"A 2-bp insertion in codon 394 of CYP11B1 causes a frameshift, premature stop at codon 469, and complete destruction of the heme-binding domain, abolishing 11β-hydroxylase activity and causing congenital adrenal hyperplasia.\",\n      \"method\": \"Gene cloning and sequencing of patient CYP11B1; identification of frameshift mutation\",\n      \"journal\": \"The Journal of clinical endocrinology and metabolism\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — mutation directly disrupts heme-binding domain with clear mechanistic basis\",\n      \"pmids\": [\"1430088\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1993,\n      \"finding\": \"The CYP11B1 gene promoter contains cooperative cis-elements including Ad1 (a CRE-like element) and Ad4 sites; the Ad4 site binds Ad4BP (a steroidogenic cell-specific transcription factor, later known as SF-1/NR5A1), and cAMP-dependent transcription requires cooperation between Ad1(CRE) and Ad4; cotransfection of Ad4BP expression vector into non-steroidogenic PC-12 cells restores forskolin-dependent CYP11B1 transcription.\",\n      \"method\": \"Transient transfection with reporter constructs, cotransfection of Ad4BP expression vector, immunoblot\",\n      \"journal\": \"Molecular endocrinology (Baltimore, Md.)\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — multiple transfection experiments in steroidogenic and non-steroidogenic cells with gain-of-function rescue, 211 citations\",\n      \"pmids\": [\"8247022\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1993,\n      \"finding\": \"Five missense mutations in CYP11B1 associated with 11β-hydroxylase deficiency all abolish enzymatic activity when expressed in vitro; mutations cluster in exons 6–8, indicating these exons encode functionally critical residues.\",\n      \"method\": \"In vitro transfection assay for enzymatic activity, sequencing\",\n      \"journal\": \"Proceedings of the National Academy of Sciences of the United States of America\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — direct in vitro enzymatic assay for multiple mutations, 165 citations\",\n      \"pmids\": [\"8506298\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1993,\n      \"finding\": \"A nonsense mutation Trp116→Stop (TGG→TAG) in exon 2 of CYP11B1 abolishes 11β-hydroxylase activity when the mutant cDNA is transfected into COS-7 cells; CYP11B2 was found to be normal in the same patient.\",\n      \"method\": \"PCR, sequencing, transfection of mutant cDNA into COS-7 cells, enzyme activity measurement\",\n      \"journal\": \"The Journal of clinical endocrinology and metabolism\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — direct in vitro expression with enzymatic activity measurement\",\n      \"pmids\": [\"7903314\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1993,\n      \"finding\": \"An AP-1 binding site in the rat CYP11B1 promoter is occupied by a complex of JunD and a Fos-related protein in adrenocortical Y1 cells; mutational analysis shows this AP-1 site (not the adjacent Ad4 site) is required for transcriptional activation of CYP11B1 in Y1 cells; immunohistochemistry shows AP-1 factor is present specifically in nuclei of CYP11B1-expressing zona fasciculata cells, implicating AP-1 in zone-specific CYP11B1 expression.\",\n      \"method\": \"Transient transfection with promoter-reporter constructs, electrophoretic mobility shift assay, immunohistochemistry, mutational analysis\",\n      \"journal\": \"Molecular and cellular biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — multiple orthogonal methods (EMSA, mutagenesis, IHC) in same study\",\n      \"pmids\": [\"7565753\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1994,\n      \"finding\": \"The bovine CYP11B gene has a distal promoter at −1.5 to −1.1 kb upstream containing two Ad4 sites and one NF-IL6 binding site; Ad4BP activates transcription through these distal Ad4 sites in a steroidogenic cell-specific manner and in cooperation with the basal promoter.\",\n      \"method\": \"Deletion analysis of upstream regions, transient transfection with CAT reporter constructs in steroidogenic cells\",\n      \"journal\": \"Journal of biochemistry\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — transfection and promoter dissection, single study\",\n      \"pmids\": [\"7798178\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1995,\n      \"finding\": \"CYP11B1 is localized to the zona fasciculata/reticularis of the human adrenal cortex by in situ hybridization; stable expression of CYP11B1 cDNA in V79 hamster cells confers 11β-hydroxylase activity, and this cell system can be used to assess inhibitor interference with the enzyme's active site.\",\n      \"method\": \"In situ hybridization with specific riboprobes, stable transfection in V79 cells, enzymatic activity measurement\",\n      \"journal\": \"Endocrine research\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — direct localization by ISH combined with functional expression in heterologous cells\",\n      \"pmids\": [\"7588406\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1995,\n      \"finding\": \"CYP11B1 was functionally expressed in COS-7 and V79 Chinese hamster cells, demonstrating 11β-hydroxylase activity; V79 cells could support CYP11B1-dependent steroid conversion without additional heterologous expression of adrenodoxin/adrenodoxin reductase.\",\n      \"method\": \"Transfection of cDNA into COS-7 and V79 cells, measurement of steroid hydroxylase activity\",\n      \"journal\": \"Endocrine research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 1 — in vitro enzymatic activity in heterologous cells, single study\",\n      \"pmids\": [\"7588408\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1995,\n      \"finding\": \"P450c11 (CYP11B1) in adrenocortical cells metabolizes and bioactivates the adrenotoxin MeSO2-DDE; this was demonstrated by correlation between forskolin induction of MeSO2-DDE and deoxycorticosterone metabolism in Y1/Kin-8 cells, inhibition of P450c11 activities by MeSO2-DDE, and direct metabolism of MeSO2-DDE after transfection of P450c11 cDNA into non-steroidogenic COS cells.\",\n      \"method\": \"Enzyme induction studies in adrenocortical cell lines, inhibition assays, transfection of CYP11B1 cDNA into COS cells, metabolite measurement\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 — multiple orthogonal approaches including transfection reconstitution and inhibition studies\",\n      \"pmids\": [\"7673111\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1996,\n      \"finding\": \"Site-directed mutagenesis of the putative I-helix region of CYP11B2 (replacing Val-320 with the CYP11B1-equivalent Ala-320) confers 11β-hydroxylase activity, while replacement of three CYP11B2 residues at positions 296, 301, 302 with CYP11B1-specific residues increases cortisol synthesis to ~85% of CYP11B1 wild-type levels and impairs aldosterone synthase activity; conversely, Val-320→Ala in CYP11B1 grants aldosterone production, demonstrating that residues 296, 301, 302, 320, and 335 in the I-helix region are key determinants of steroid hydroxylation regiospecificity.\",\n      \"method\": \"Computer modeling and site-directed mutagenesis, transfection, steroid product analysis\",\n      \"journal\": \"Endocrine research\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — reconstitution via mutagenesis with direct enzymatic readout\",\n      \"pmids\": [\"8969896\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1997,\n      \"finding\": \"Three missense mutations in CYP11B1 (N133H, T319M, P42S) associated with non-classic 11β-hydroxylase deficiency partially reduce enzymatic activity when expressed in vitro, in contrast to mutations causing classic disease which abolish activity completely.\",\n      \"method\": \"In vitro expression in COS-7 cells, enzymatic activity measurement\",\n      \"journal\": \"Human molecular genetics\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — direct in vitro enzymatic assay with multiple mutations\",\n      \"pmids\": [\"9302260\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1998,\n      \"finding\": \"Replacement of Ser-288 and Val-320 of CYP11B1 with the corresponding CYP11B2 residues (Gly and Ala) confers 18-oxidase activity on CYP11B1, enabling synthesis of 18-hydroxycortisol and 18-oxocortisol from 11-deoxycortisol; additional substitutions encoded in exons 4, 5, and 6 of CYP11B2 further enhance this activity.\",\n      \"method\": \"Recombinant cDNA construction and transfection, steroid product analysis by HPLC/RIA\",\n      \"journal\": \"The Journal of clinical endocrinology and metabolism\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — mutagenesis with direct enzymatic readout defining substrate-binding determinants\",\n      \"pmids\": [\"9814482\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1998,\n      \"finding\": \"Replacement of Val-320 and Ala-335 of CYP11B1 with CYP11B2-specific amino acids confers 18-oxidase function (20% of CYP11B2 wild-type activity) on CYP11B1; the sequence spanned by amino acids 301–335 constitutes part of the substrate-binding site in both CYP11B1 and CYP11B2; C-terminal residues 471–494 are insignificant for stereo- and regiospecificity.\",\n      \"method\": \"Residue-swapping mutagenesis, transfection, chimeric protein construction, steroid product analysis\",\n      \"journal\": \"European journal of biochemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — reconstitution via systematic mutagenesis identifying substrate-binding residues\",\n      \"pmids\": [\"9546661\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1998,\n      \"finding\": \"Dahl salt-resistant (DR) rat CYP11B1 carries five missense mutations; E. coli expression shows DR-CYP11B1 has similar 11β-hydroxylase activity to wild-type but substantially reduced 18-hydroxylase and 19-hydroxylase activities; V381L and I384L double substitution accounts for the decreased 18-OHase activity, and V443M accounts for reduced 19-OHase activity.\",\n      \"method\": \"Expression in E. coli, enzymatic activity measurement with steroid substrates, single and double mutant analysis\",\n      \"journal\": \"European journal of biochemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — direct in vitro reconstitution in E. coli with defined single and double mutants\",\n      \"pmids\": [\"9874258\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1998,\n      \"finding\": \"ACTH stimulates CYP11B1 transcription via AP-1 transcription factors (Jun/Fos family) binding to the CYP11B1 promoter; ACTH/cAMP induces changes in AP-1 composition (increasing c-Jun/c-Fos over constitutive JunD/Fra-2), and overexpression of c-Jun and c-Fos transactivates the CYP11B1 promoter; Ad4BP is not required for basal or ACTH-induced CYP11B1 transcription in rat adrenocortical cells.\",\n      \"method\": \"Transient transfection, promoter-reporter assays, EMSA, overexpression of AP-1 components\",\n      \"journal\": \"European journal of biochemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — multiple orthogonal methods (transfection, EMSA, overexpression) in same study\",\n      \"pmids\": [\"9746364\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1999,\n      \"finding\": \"CYP11B1 and CYP11A1 compete for reducing equivalents from adrenodoxin in COS-1 cells upon cotransfection; coexpression of adrenodoxin partially rescues CYP11B activity; bovine CYP11A1 cotransfected with bovine CYP11B1 paradoxically stimulates 11β-hydroxylation, indicating species-specific differences in the regulatory interaction between CYP11A1, CYP11B1/B2, and the adrenodoxin electron transfer chain.\",\n      \"method\": \"Cotransfection of cDNAs into COS-1 cells, steroid product analysis\",\n      \"journal\": \"European journal of biochemistry\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — direct cotransfection functional experiments, single study\",\n      \"pmids\": [\"10411633\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2000,\n      \"finding\": \"Two novel splice donor site mutations in CYP11B1 (a conservative exon 5 transversion causing exon skipping and an IVS8+4A→G intron 8 mutation) abolish 11β-hydroxylase activity; minigene/RT-PCR analysis shows IVS8+4 mutation causes exon 8 skipping, producing a truncated 43 kDa protein lacking the heme-binding domain.\",\n      \"method\": \"RT-PCR, sequencing, in vitro cell culture enzyme assay, Western blot, mitochondrial activity assay\",\n      \"journal\": \"The Journal of clinical endocrinology and metabolism\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 — mRNA analysis with Western blot and enzymatic assay confirming mechanism\",\n      \"pmids\": [\"11095433\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2001,\n      \"finding\": \"A chimeric CYP11B2/CYP11B1 gene (CYP11B2 promoter and exons 1-6, CYP11B1 exons 7-9) retains 11β-hydroxylase and aldosterone synthase activity when expressed in COS-1 cells, but causes 11β-hydroxylase deficiency in vivo because the CYP11B2 promoter does not drive expression in the zona fasciculata/reticularis where cortisol is synthesized.\",\n      \"method\": \"Mutant cDNA expression in COS-1 cells, steroid product assay, Southern blot\",\n      \"journal\": \"The Journal of clinical endocrinology and metabolism\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — in vitro expression combined with in vivo promoter context analysis\",\n      \"pmids\": [\"11443188\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2001,\n      \"finding\": \"Adrenodoxin (Adx) mutants with C-terminal modifications (e.g., S112W) show dramatically altered rate constants for heme reduction of CYP11A1 but not of CYP11B1; the kinetics of Adx–CYP11B1 interaction are less sensitive to adrenodoxin structural changes than Adx–CYP11A1 interaction, indicating distinct protein-protein interaction requirements for different mitochondrial P450 partners.\",\n      \"method\": \"Kinetic measurements of heme reduction rates with adrenodoxin wild-type and 8 site-directed mutants, CO-complex formation assay\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — in vitro kinetic reconstitution with systematic mutagenesis of electron transfer partner\",\n      \"pmids\": [\"11459837\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2003,\n      \"finding\": \"Deletion of CYP11B1 and CYP11B2 by unequal recombination leaving only a CYP11B2(5')/CYP11B1(3') hybrid gene causes 11β-hydroxylase deficiency because the CYP11B2 promoter cannot drive sufficient expression in the zona fasciculata; the remaining hybrid cDNA, when expressed in COS-1 cells, retains partial 11β-hydroxylase activity, demonstrating that the CYP11B2 promoter context in vivo, not the coding sequence, is the primary defect.\",\n      \"method\": \"PCR, Southern blot, sequencing, COS-1 cell expression with steroid assay\",\n      \"journal\": \"The Journal of clinical endocrinology and metabolism\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — in vitro expression plus genomic structural analysis defining promoter-dependent mechanism\",\n      \"pmids\": [\"11443188\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2005,\n      \"finding\": \"Two CYP11B1 missense mutations (W116C, L299P) and an in-frame 3-bp deletion (ΔF438) markedly reduce or abolish 11β-hydroxylase activity in COS-7 cells (2.9%, 1.2%, and 0% of wild-type, respectively); 3D modeling suggests W116C disrupts conformational change for substrate access/product release, L299P alters I-helix position relative to heme, and ΔF438 disarranges the heme group.\",\n      \"method\": \"In vitro expression in COS-7 cells, enzymatic activity assay, 3D protein homology modeling\",\n      \"journal\": \"The Journal of clinical endocrinology and metabolism\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — direct in vitro enzymatic assay combined with structural modeling explaining mechanism\",\n      \"pmids\": [\"15755848\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2006,\n      \"finding\": \"PCB126 up-regulates CYP11B1 mRNA expression in H295R human adrenocortical cells not through AhR-mediated transcriptional activation but by increasing posttranscriptional mRNA stability; an internal CYP11B1 mRNA region (nucleotides 881-1285) is important for PCB126-mediated transcript stabilization.\",\n      \"method\": \"Promoter analysis, RNA degradation assays, AhR antagonist experiments, region-specific mRNA analysis\",\n      \"journal\": \"Endocrinology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — multiple orthogonal approaches (promoter assay, RNA stability, antagonist) identifying posttranscriptional mechanism\",\n      \"pmids\": [\"16396990\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2007,\n      \"finding\": \"Coexpression of adrenodoxin and adrenodoxin reductase with CYP11B1 in Schizosaccharomyces pombe increases 11β-hydroxylase activity 3.4-fold; position 78 (isoleucine) is critical for optimal 11β-hydroxylation activity, and position 23 (Gly→Arg mutation) enhances CYP11B1 expression 3.3-fold.\",\n      \"method\": \"Site-directed mutagenesis, stable expression in S. pombe, enzymatic activity measurement, coexpression experiments\",\n      \"journal\": \"Journal of biotechnology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — mutagenesis combined with coexpression of electron transfer partners, functional readout\",\n      \"pmids\": [\"17935813\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2008,\n      \"finding\": \"Cyp11b1 null mice (exons 3-7 replaced by ECFP cDNA) show glucocorticoid deficiency, mineralocorticoid (DOC) excess, adrenal hyperplasia, mild hypertension, hypokalemia, glucose intolerance, and female infertility with absence of corpora lutea; these phenotypes confirm that CYP11B1 is the rate-limiting enzyme for glucocorticoid synthesis in the zona fasciculata and that deoxycorticosterone accumulation causes mineralocorticoid excess.\",\n      \"method\": \"Targeted gene knockout, urinary steroid profiling, immunocytochemistry, phenotypic characterization including reproductive assessment\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — clean KO with multiple defined phenotypic readouts including steroid profiling\",\n      \"pmids\": [\"19029289\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2010,\n      \"finding\": \"Seven novel CYP11B1 mutations show graded functional impairment: mutations causing classic 11β-OHD abolish or nearly abolish activity (<5% WT), while mutations in non-classic patients retain 25–40% activity; this establishes a genotype-phenotype correlation where residual enzymatic activity determines disease severity.\",\n      \"method\": \"In vitro expression in COS-7 cells, enzymatic activity measurement, 3D computational modeling\",\n      \"journal\": \"The Journal of clinical endocrinology and metabolism\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — systematic in vitro activity quantification for multiple mutants\",\n      \"pmids\": [\"20089618\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"miR-10b, induced by hypoxia/HIF-1α, directly targets the 3′-UTR of CYP11B1 mRNA and represses CYP11B1 expression; luciferase reporter assays with the CYP11B1 3′-UTR combined with miR-10b overexpression and knockdown confirm this post-transcriptional regulation.\",\n      \"method\": \"Luciferase 3′-UTR reporter assay, miRNA overexpression and knockdown in H295R cells, TaqMan miRNA arrays\",\n      \"journal\": \"Marine pollution bulletin\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — reporter assay plus gain- and loss-of-function miRNA experiments, single study\",\n      \"pmids\": [\"24768260\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"Hypomethylation of the CYP11B1 promoter is associated with cortisol overproduction in cortisol-producing adenomas (CPA); reporter assays demonstrate that DNA methylation reduces CYP11B1 promoter activity; CPA carrying somatic PRKACA or GNAS mutations show significantly hypomethylated CYP11B1 promoters, linking cAMP pathway activation to epigenetic derepression of CYP11B1.\",\n      \"method\": \"Methylation analysis of promoter CpG sites, luciferase reporter assay with methylated and unmethylated constructs, somatic mutation analysis\",\n      \"journal\": \"Scientific reports\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — reporter assay plus methylation analysis with somatic mutation correlation, single study\",\n      \"pmids\": [\"28894201\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2011,\n      \"finding\": \"The Ad5 binding element in the CYP11B1 core promoter is required for basal expression; ERRα (estrogen-related receptor α) is the transcription factor interacting with the Ad5 site during basal CYP11B1 transcription; Alu elements act as enhancers in the CYP11B1 upstream region, but their effect is blocked by an intervening L1 retrotransposon (CYP11B1-L1.2) inserted between the Alu elements and the core promoter.\",\n      \"method\": \"Promoter deletion/mutation analysis, transcription factor identification by reporter assay, ERRα identification, functional dissection of transposable elements\",\n      \"journal\": \"Steroids\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — multiple reporter and deletion experiments identifying transcription factor, single study\",\n      \"pmids\": [\"22079243\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"CYP11B1 catalyzes a one-step 11β-hydroxylation of 11-deoxycortisol to cortisol (regio- and stereoselective); a G23R mutation enhances CYP11B1 protein expression 3.3-fold in E. coli; optimization of the adrenodoxin/adrenodoxin reductase coexpression and CYP11B1 mutagenesis achieved 0.84 g cortisol/L/day in whole-cell biotransformation.\",\n      \"method\": \"Recombinant E. coli whole-cell system, site-directed mutagenesis, directed evolution with fluorescence-based screening, cortisol quantification\",\n      \"journal\": \"Microbial cell factories\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — reconstituted in vitro/whole-cell system with mutagenesis defining residues important for expression and activity\",\n      \"pmids\": [\"25880059\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"CYP11B1 is a mitochondrial cytochrome P450 (encoded on chromosome 8q22) that performs regio- and stereoselective 11β-hydroxylation of 11-deoxycortisol to cortisol as the final and rate-limiting step in glucocorticoid biosynthesis; it receives electrons from NADPH via adrenodoxin reductase and adrenodoxin, is expressed specifically in the zona fasciculata/reticularis under transcriptional control of AP-1 factors (induced by ACTH/cAMP), Ad4BP/SF-1, and a CRE/Ad1 element, and its promoter activity is also regulated by DNA methylation and miR-10b-mediated posttranscriptional repression; key residues in the I-helix region (particularly positions 288, 301, 302, 320, 335) determine substrate-binding specificity and distinguish CYP11B1's exclusive 11β-hydroxylase activity from the multi-step aldosterone synthase activity of the closely related CYP11B2.\"\n}\n```\n\n--- ROUND 2 (R2/R3, augmented corpus) ---\n\n```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 1987,\n      \"finding\": \"CYP11B1 (P450c11) encodes a 479-amino-acid mature protein (plus a 24-residue mitochondrial signal sequence) that catalyzes steroid 11β-hydroxylation; cDNA cloning established the primary structure and chromosomal localization to 8q.\",\n      \"method\": \"cDNA cloning and sequencing; in vitro translation; chromosomal hybridization\",\n      \"journal\": \"Proceedings of the National Academy of Sciences of the United States of America\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — original cDNA cloning with full sequence determination, foundational paper\",\n      \"pmids\": [\"3499608\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1989,\n      \"finding\": \"CYP11B1 and the paralog CYP11B2 each contain nine exons (introns in identical positions to CYP11A); the encoded proteins are 93% identical to each other, yet their 5'-flanking regions have diverged considerably, consistent with distinct transcriptional regulation. CYP11B2 transcripts were not detected in normal adrenal mRNA.\",\n      \"method\": \"Genomic library cloning, sequencing, and Northern blot\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — complete genomic characterization with sequence analysis, foundational study\",\n      \"pmids\": [\"2592361\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1990,\n      \"finding\": \"CYP11B1 (P-45011β) expressed in COS-7 cells exhibits exclusively 11β-hydroxylase activity, converting 11-deoxycortisol to cortisol, but fails to catalyze aldosterone or 18-oxocortisol synthesis, distinguishing it functionally from CYP11B2.\",\n      \"method\": \"Transient transfection of full-length cDNA in COS-7 cells; steroid conversion assay\",\n      \"journal\": \"FEBS letters\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — direct enzymatic activity demonstrated in heterologous expression system\",\n      \"pmids\": [\"2401360\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1991,\n      \"finding\": \"A single base substitution in CYP11B1 exon 8 (Arg-448→His, within the heme-binding peptide containing the cysteine heme-ligand) abolishes 11β-hydroxylase activity, demonstrating that Arg-448 is essential for enzymatic function.\",\n      \"method\": \"PCR-selective amplification of CYP11B1, DNA sequencing; family linkage\",\n      \"journal\": \"The Journal of clinical investigation\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — identified functionally critical residue in heme-binding domain with strong genetic segregation evidence\",\n      \"pmids\": [\"2022736\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1992,\n      \"finding\": \"CYP11B1 encodes a protein with only 11β-hydroxylase activity; the hybrid gene in glucocorticoid-suppressible hyperaldosteronism (GSH) has CYP11B1 5'-regulatory and coding sequences fused to 3'-CYP11B2 coding sequences. Transfection experiments showed that hybrids retaining ≤3 CYP11B1 exons could synthesize aldosterone near wild-type CYP11B2 levels, while hybrids containing ≥5 CYP11B1 exons could not, mapping aldosterone synthase determinants to exons 4–9 of CYP11B2.\",\n      \"method\": \"Transfection of hybrid cDNAs into COS-1 cells; aldosterone synthesis assay\",\n      \"journal\": \"Proceedings of the National Academy of Sciences of the United States of America\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — reconstitution by transfection of defined hybrid constructs with enzymatic readout\",\n      \"pmids\": [\"1518866\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1992,\n      \"finding\": \"Hereditary hypertension (glucocorticoid-remediable aldosteronism) is caused by chimeric gene duplications that fuse CYP11B1 regulatory sequences to CYP11B2 coding sequences, resulting in ectopic aldosterone synthase activity regulated by ACTH; crossing-over occurs between introns 2 and 4.\",\n      \"method\": \"Southern blot, genomic PCR, chimeric gene characterization in 12 kindreds\",\n      \"journal\": \"Nature genetics\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — direct genetic demonstration of regulatory/coding domain swap with functional consequence replicated across 12 families\",\n      \"pmids\": [\"1303253\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1992,\n      \"finding\": \"CYP11B1 exon 7 frameshift (2-bp insertion at codon 394) destroys the heme-binding domain and completely abolishes 11β-hydroxylase activity.\",\n      \"method\": \"Gene cloning and sequencing; inference from protein structure\",\n      \"journal\": \"The Journal of clinical endocrinology and metabolism\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — frameshift mutation directly explains complete loss of function; mechanistic link to heme-binding domain established\",\n      \"pmids\": [\"1430088\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1992,\n      \"finding\": \"CYP11B1 promoter activity requires a CRE-like Ad1 element and upstream elements Ad3/Ad4 for full cAMP-dependent transcription; both elements must cooperate for maximal cAMP response in steroidogenic cells.\",\n      \"method\": \"Transient transfection reporter assay with deletion/mutation constructs; in vitro transcription; CREB/nuclear factor binding assays\",\n      \"journal\": \"Journal of biochemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — multiple orthogonal approaches (reporter assay, in vitro transcription, EMSA) in same study\",\n      \"pmids\": [\"1336011\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1993,\n      \"finding\": \"All five known missense mutations causing 11β-hydroxylase deficiency (including Arg-448→His, Arg-384→Gly, and three others) abolish enzymatic activity when expressed in vitro; mutations cluster in exons 6–8, suggesting these regions harbor functionally critical residues.\",\n      \"method\": \"In vitro transfection assay (COS cell expression) of mutant cDNAs; steroid conversion measurement\",\n      \"journal\": \"Proceedings of the National Academy of Sciences of the United States of America\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — direct in vitro enzymatic assay of multiple loss-of-function mutations, establishing exon 6–8 as functionally critical\",\n      \"pmids\": [\"8506298\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1993,\n      \"finding\": \"Ad4BP (steroidogenic cell-specific transcription factor, now SF-1/NR5A1) binds the Ad4 cis-element in the CYP11B promoter and is required for cAMP-dependent, steroidogenic cell-specific transcription; its absence in non-steroidogenic cells accounts for lack of CYP11B expression there.\",\n      \"method\": \"Transient transfection reporter assay; immunoblot; cotransfection of Ad4BP expression vector\",\n      \"journal\": \"Molecular endocrinology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — gain-of-function cotransfection plus protein immunoblot demonstrate direct role of Ad4BP\",\n      \"pmids\": [\"8247022\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1993,\n      \"finding\": \"A nonsense mutation (Trp116→Stop) in CYP11B1 exon 2 results in complete absence of 11β-hydroxylase activity in mitochondria of transfected COS-7 cells, demonstrating that intact protein is required for activity.\",\n      \"method\": \"PCR, sequencing, RFLP, COS-7 cell transfection and enzyme activity assay\",\n      \"journal\": \"The Journal of clinical endocrinology and metabolism\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — direct demonstration of loss of function via heterologous expression\",\n      \"pmids\": [\"7903314\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1994,\n      \"finding\": \"Two Ad4 sites in the distal promoter of bovine CYP11B (−1.5 to −1.1 kb) confer steroidogenic cell-specific and cAMP-stimulated transcriptional activation through Ad4BP; distal and proximal promoters interact in a gene-specific manner.\",\n      \"method\": \"Transient transfection of CAT reporter constructs with distal promoter fragments in steroidogenic and non-steroidogenic cells\",\n      \"journal\": \"Journal of biochemistry\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — defined cis-element mapped by reporter deletion; cell-type specificity confirmed\",\n      \"pmids\": [\"7798178\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1995,\n      \"finding\": \"CYP11B1 expressed in COS-1 cells and stably in V79 Chinese hamster cells retains 11β-hydroxylase activity without requiring exogenous electron-transfer proteins, indicating that hamster cells provide sufficient endogenous adrenodoxin/adrenodoxin reductase-like activity.\",\n      \"method\": \"cDNA cloning; COS-7 transient transfection; V79 stable transfection; Northern blot; steroid hydroxylase activity assay\",\n      \"journal\": \"Endocrine research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 1 — direct enzymatic assay in two expression systems\",\n      \"pmids\": [\"7588408\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1995,\n      \"finding\": \"CYP11B1 (P450c11β) metabolizes and bioactivates the adrenotoxic xenobiotic MeSO2-DDE, establishing that this mitochondrial steroidogenic P450 can also perform xenobiotic metabolism; activity demonstrated by correlation with DOC metabolism induction by forskolin, inhibition of P450c11-dependent activities by MeSO2-DDE, and COS cell transfection experiments.\",\n      \"method\": \"Correlation of enzyme induction; inhibition assays in Y1 and Kin-8 cells; COS cell transfection with CYP11B1 cDNA followed by MeSO2-DDE metabolism assay\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — multiple orthogonal approaches including reconstitution in COS cells demonstrate xenobiotic substrate activity\",\n      \"pmids\": [\"7673111\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1995,\n      \"finding\": \"An AP-1 transcription factor complex (containing JunD and a Fos-related protein) binds adjacent to the Ad4BP site in the rat CYP11B1 promoter; AP-1 binding suppresses Ad4BP binding, and the AP-1 site (not the Ad4 site) drives transcriptional activation in zona fasciculata cells. AP-1 factor is present in nuclei of CYP11B1-expressing zona fasciculata cells but not in other zones.\",\n      \"method\": \"Transient transfection with promoter mutants in Y1 cells; EMSA with nuclear extracts; immunohistochemistry\",\n      \"journal\": \"Molecular and cellular biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — mutational analysis plus EMSA plus immunohistochemistry provide convergent mechanistic evidence\",\n      \"pmids\": [\"7565753\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1996,\n      \"finding\": \"Point mutations in the putative I-helix of CYP11B1 (e.g., Val-320→Ala, the CYP11B2-specific residue) confer aldosterone synthesis (18-oxidase activity) on CYP11B1, while the reciprocal CYP11B2 mutations at positions 296, 301, 302, and 320 elevate its 11β-hydroxylase activity and diminish aldosterone synthase activity, identifying this region as determining regioselectivity.\",\n      \"method\": \"Site-directed mutagenesis; COS cell expression; steroid product profiling\",\n      \"journal\": \"Endocrine research\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — reconstitution with mutagenesis; defined amino acid positions controlling enzymatic specificity\",\n      \"pmids\": [\"8969896\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1997,\n      \"finding\": \"Non-classic 11β-hydroxylase deficiency is caused by partial-loss-of-function missense mutations in CYP11B1 (e.g., N133H, T319M, P42S) that reduce but do not abolish enzymatic activity when expressed in vitro, establishing a genotype–phenotype correlation.\",\n      \"method\": \"In vitro expression in COS cells; steroid conversion assay\",\n      \"journal\": \"Human molecular genetics\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — direct enzymatic quantification of multiple mutant enzymes\",\n      \"pmids\": [\"9302260\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1998,\n      \"finding\": \"Replacement of CYP11B1 residues at positions 320 (Val→Ala) and 335 with CYP11B2-specific residues confers 18-oxidase activity (~20% of CYP11B2 WT), converting CYP11B1 into a partial aldosterone synthase; combining substitutions at positions 296, 301, 302, 320, 335, and 339 did not further enhance activity. The region spanning residues 301–335 constitutes part of the substrate-binding site.\",\n      \"method\": \"Site-directed mutagenesis; chimeric protein construction; COS cell transfection; steroid product analysis\",\n      \"journal\": \"European journal of biochemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — systematic reciprocal mutagenesis defining substrate-binding site residues\",\n      \"pmids\": [\"9546661\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1998,\n      \"finding\": \"CYP11B1 hybrid enzymes with CYP11B2 residues at Ser-288 and Val-320 can catalyze conversion of 11-deoxycortisol to cortisol, 18-hydroxycortisol, and 18-oxocortisol; additional substitutions from CYP11B2 exons 4–6 further enhance 18-hydroxylcortisol and 18-oxocortisol production.\",\n      \"method\": \"Recombinant hybrid cDNA construction; cell transfection; steroid product measurement\",\n      \"journal\": \"The Journal of clinical endocrinology and metabolism\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — defined hybrid enzymes expressed and enzymatically characterized\",\n      \"pmids\": [\"9814482\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1998,\n      \"finding\": \"CYP11B1 expressed in E. coli retains 11β-hydroxylase activity; Dahl salt-resistant rat CYP11B1 (DR-CYP11B1) has decreased 18-hydroxylase and 19-hydroxylase activities compared to WT; the double mutation V381L/I384L accounts for decreased 18-OHase activity, and V443M accounts for decreased 19-OHase activity.\",\n      \"method\": \"Bacterial expression; site-directed mutagenesis; steroid conversion assays\",\n      \"journal\": \"European journal of biochemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — E. coli reconstitution with mutagenesis defining key residues for 18-OHase and 19-OHase activities\",\n      \"pmids\": [\"9874258\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1998,\n      \"finding\": \"ACTH-stimulated transcription of rat CYP11B1 requires an AP-1 binding site in the 5'-flanking region; corticotropin induces compositional changes in AP-1 factors (increasing c-Jun/c-Fos over constitutive JunD/Fra-2) via a cAMP-dependent pathway, and c-Jun/c-Fos overexpression transactivates CYP11B1 more strongly than other combinations.\",\n      \"method\": \"Transient transfection with promoter mutants; AP-1 supershift EMSA; cAMP treatment; in vivo corticotropin treatment + mRNA analysis\",\n      \"journal\": \"European journal of biochemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — multiple orthogonal methods (transfection, EMSA, in vivo) defining mechanism of ACTH-induced transcription\",\n      \"pmids\": [\"9746364\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1999,\n      \"finding\": \"CYP11B1 and CYP11A1 co-expressed in COS-1 cells compete for reducing equivalents from the endogenous electron-transfer system; excess adrenodoxin resolves this competition. Bovine CYP11B1 co-expressed with CYP11A1 and adrenodoxin shows stimulated 11β-hydroxylation but reduced 18-hydroxycorticosterone and aldosterone formation, indicating functional interaction between the mitochondrial P450 enzymes.\",\n      \"method\": \"Co-transfection of COS-1 cells; steroid product analysis with and without exogenous adrenodoxin\",\n      \"journal\": \"European journal of biochemistry\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — competition for electron donor established by co-transfection with adrenodoxin rescue\",\n      \"pmids\": [\"10411633\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2000,\n      \"finding\": \"The CRE/Ad1 element in the hCYP11B1 promoter is required for both basal expression and agonist (angiotensin II, potassium, cAMP, forskolin) responsiveness; mutation of this element reduces basal activity and agonist response. CREB, ATF-1, and ATF-2 bind this element in vitro, with ATF-2 complexes seen in adrenocortical nuclear extracts.\",\n      \"method\": \"Transient transfection reporter assays in H295R cells; EMSA with in vitro prepared and nuclear extract proteins\",\n      \"journal\": \"Endocrine research\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — mutational analysis plus EMSA with identified transcription factors\",\n      \"pmids\": [\"11196473\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2001,\n      \"finding\": \"Adrenodoxin mutants with C-terminal truncation and introduction of Trp at position 112 (e.g., S112W) show markedly faster reduction kinetics with CYP11A1 but not CYP11B1, demonstrating that CYP11A1 and CYP11B1 have distinct requirements for adrenodoxin-mediated electron transfer. CYP11B1 reduction rate constants were similar across adrenodoxin mutants, unlike CYP11A1.\",\n      \"method\": \"Stopped-flow kinetics of CO-complex formation; substrate conversion assays; site-directed mutagenesis of adrenodoxin\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — quantitative kinetic analysis with multiple adrenodoxin mutants, demonstrating differential protein-protein interaction requirements\",\n      \"pmids\": [\"11459837\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2002,\n      \"finding\": \"The steroidogenic factor SF-1 (Ad4BP/NR5A1) positively regulates CYP11B1 transcription (increasing reporter activity) via the Ad4 element in the promoter; mutation of the Ad4 element blocks agonist stimulation of CYP11B1 but not CYP11B2. EMSA shows SF-1 binds the CYP11B1 Ad4 element. Conversely, SF-1 overexpression inhibits CYP11B2 expression.\",\n      \"method\": \"Transient transfection reporter assays; EMSA; SF-1 siRNA knockdown; doxycycline-inducible SF-1 overexpression in H295R cells\",\n      \"journal\": \"Journal of molecular endocrinology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — gain- and loss-of-function plus EMSA with defined SF-1 binding site\",\n      \"pmids\": [\"11932209\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2005,\n      \"finding\": \"CYP11B1 missense mutations W116C and L299P reduce enzymatic activity to ~3% and ~1% of WT respectively, and ΔF438 abolishes activity entirely; 3D modeling suggests W116C disrupts conformational change for substrate access/product release, L299P alters I-helix positioning relative to heme, and ΔF438 causes steric disarrangement of the heme group.\",\n      \"method\": \"COS-7 cell in vitro expression; steroid conversion assay; 3D computational modeling\",\n      \"journal\": \"The Journal of clinical endocrinology and metabolism\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1+2 — direct enzymatic quantification combined with structural modelling of multiple mutations\",\n      \"pmids\": [\"15755848\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2006,\n      \"finding\": \"PCB126 up-regulates CYP11B1 and CYP11B2 mRNA not through AhR-mediated transcriptional activation but by stabilizing mRNA post-transcriptionally; an internal region of CYP11B1 mRNA (nucleotides 881–1285) is important for PCB126-mediated transcript stabilization.\",\n      \"method\": \"RNA degradation assays; promoter analysis; AhR antagonist treatment; mRNA stability assays with defined CYP11B1 mRNA fragments in H295R cells\",\n      \"journal\": \"Endocrinology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — RNA stability mechanism defined with mRNA region mapping\",\n      \"pmids\": [\"16396990\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2007,\n      \"finding\": \"Co-expression of adrenodoxin and adrenodoxin reductase with CYP11B1 in fission yeast (S. pombe) increases 11β-hydroxylation activity 3.4-fold; site-directed mutagenesis at position 78 (isoleucine) of CYP11B1 confers highest hydroxylation activity, demonstrating that the redox partner system and specific amino acid identity at position 78 are rate-limiting for cortisol production.\",\n      \"method\": \"S. pombe expression system; site-directed mutagenesis; cortisol production measurement\",\n      \"journal\": \"Journal of biotechnology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — reconstitution with co-expression and mutagenesis demonstrating electron-transfer dependence and key residue\",\n      \"pmids\": [\"17935813\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2008,\n      \"finding\": \"Purified recombinant human CYP11B1 (co-expressed with GroES/GroEL chaperones in E. coli) retains 11β-hydroxylase activity with ~75% NADPH coupling efficiency for both 11-deoxycortisol and 11-deoxycorticosterone substrates. Biacore and stopped-flow measurements indicate CYP11B1 possesses more than one binding site for adrenodoxin, suggesting formation of multiple productive complexes.\",\n      \"method\": \"E. coli expression with chaperone co-expression; purification to homogeneity; mass spectrometry; substrate conversion assays; Biacore (SPR); stopped-flow spectroscopy; CD spectroscopy\",\n      \"journal\": \"The FEBS journal\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — reconstituted purified enzyme with multiple biophysical and biochemical methods\",\n      \"pmids\": [\"18215163\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2008,\n      \"finding\": \"Cyp11b1 knockout mice (exons 3–7 replaced by ECFP cDNA) lack 11β-hydroxylase activity (confirmed by urinary steroid profiles and absent immunostaining), exhibit glucocorticoid deficiency, mineralocorticoid excess (DOC accumulation), adrenal hyperplasia, mild hypertension, hypokalemia, glucose intolerance, and female infertility due to anovulation.\",\n      \"method\": \"Targeted gene knockout (exon replacement); urinary steroid profiling; immunocytochemistry; blood pressure measurement; reproductive phenotyping\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — clean genetic knockout with multiple defined phenotypic readouts establishing in vivo functions\",\n      \"pmids\": [\"19029289\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2010,\n      \"finding\": \"Novel CYP11B1 missense mutations causing classic 11β-OHD (W116G, A165D, K254_A259del) show absent or near-absent 11β-hydroxylase activity; mutations causing non-classic 11β-OHD (P159L, M88I) show partial activity (~25% and ~40% of WT respectively), demonstrating a direct correlation between residual enzyme activity level and disease severity.\",\n      \"method\": \"COS7 cell in vitro expression system; steroid conversion assay; 3D computational modeling\",\n      \"journal\": \"The Journal of clinical endocrinology and metabolism\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — quantitative enzymatic analysis of 7 mutations with clear genotype-phenotype correlation\",\n      \"pmids\": [\"20089618\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2011,\n      \"finding\": \"The Ad5/SF-1 binding element in the CYP11B1 core promoter is required for basal expression; ERRα is the transcription factor that interacts with the Ad5 site during basal expression. Insertion of an L1 transposable element (CYP11B1-L1.2) between the Alu elements and the proximal core promoter suppresses Alu enhancer activity on CYP11B1; deletion of CYP11B1-L1.2 greatly increases promoter activity.\",\n      \"method\": \"Promoter deletion/mutation reporter assays; transcription factor identification by EMSA; Alu and L1 element functional analysis; luciferase assays in H295R cells\",\n      \"journal\": \"Steroids\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — defined cis-elements and identified ERRα as binding transcription factor with functional assays\",\n      \"pmids\": [\"22079243\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2011,\n      \"finding\": \"Nonhydroxylated flavones (3',4'-dimethoxyflavone, α- and β-naphthoflavone) up-regulate CYP11B1 expression and cortisol production in H295R cells; this induction requires the Ad5 element (−121/−106) in the CYP11B1 promoter and is partially dependent on PKA signaling (sensitive to H-89) but independent of AhR and ERK1/2 signaling.\",\n      \"method\": \"H295R cell model; qRT-PCR; promoter reporter assays with Ad5 mutations; pharmacological inhibitors; western blot\",\n      \"journal\": \"Toxicology and applied pharmacology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — promoter element mapping combined with pharmacological dissection of signaling pathway\",\n      \"pmids\": [\"22172629\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"miR-10b is a hypoxia-inducible microRNA that negatively regulates CYP11B1 and CYP11B2 at the post-transcriptional level by targeting their 3'-UTRs; luciferase reporter assays with 3'-UTR constructs and miRNA overexpression/knockdown confirmed this interaction in H295R cells.\",\n      \"method\": \"miRNA array; in silico target prediction; luciferase 3'-UTR reporter assays; miR-10b overexpression and knockdown in H295R cells\",\n      \"journal\": \"Marine pollution bulletin\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — validated by 3'-UTR reporter assay and overexpression/knockdown experiments\",\n      \"pmids\": [\"24768260\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"An E. coli whole-cell system co-expressing CYP11B1, adrenodoxin, and adrenodoxin reductase selectively converts 11-deoxycortisol to cortisol; CYP11B1 expression was enhanced 3.3-fold by mutagenesis of Gly-23→Arg, improving cortisol yield 2.6-fold. Additional Adx copies further accelerated conversion, demonstrating that electron-transfer chain stoichiometry is rate-limiting.\",\n      \"method\": \"E. coli whole-cell biocatalysis; site-directed mutagenesis; copy-number variation of Adx; LC-MS cortisol quantification; directed evolution screening\",\n      \"journal\": \"Microbial cell factories\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — reconstituted three-component system with mutagenesis and quantitative optimization\",\n      \"pmids\": [\"25880059\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"DNA hypomethylation of the CYP11B1 promoter is associated with increased CYP11B1 expression and cortisol overproduction in cortisol-producing adenomas (CPA); reporter assays confirmed that DNA methylation directly reduces CYP11B1 promoter activity. Somatic mutations in PRKACA or GNAS in CPA are associated with significant CYP11B1 promoter hypomethylation.\",\n      \"method\": \"Bisulfite sequencing of CYP11B1 promoter; methylated reporter assay; comparison between CPA, adjacent adrenal, and white blood cells; somatic mutation genotyping\",\n      \"journal\": \"Scientific reports\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — direct reporter assay demonstrating methylation represses CYP11B1 promoter, with in vivo correlation to adenoma somatic mutations\",\n      \"pmids\": [\"28894201\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"Computational 3D modeling of 25 CYP11B1 missense mutations reveals that modifications in the heme-binding site (R374W, R448C), substrate-binding site (W116C), or protein stability (L299P, G267S) predict severe 11β-hydroxylase deficiency, providing a structural basis for genotype-severity correlation in the largest cohort (108 patients) studied to date.\",\n      \"method\": \"Homology-based computational structural modeling; clinical/hormonal correlation with genotype in 108 patients\",\n      \"journal\": \"Proceedings of the National Academy of Sciences of the United States of America\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 4 computational + Tier 2 clinical correlation — large cohort provides strong validation but mechanism inferred by modeling\",\n      \"pmids\": [\"28228528\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"CYP11B1 encodes a mitochondrial cytochrome P450 (11β-hydroxylase) that catalyzes the final step of cortisol biosynthesis by converting 11-deoxycortisol to cortisol via 11β-hydroxylation, receiving electrons from NADPH through adrenodoxin reductase and adrenodoxin (with which it forms multiple productive complexes); its substrate-binding site and regioselectivity are determined by residues in the I-helix region (especially positions 301–335), its heme-binding domain (Cys and Arg-448) is essential for catalysis, its transcription in zona fasciculata is driven by cooperative action of the CRE/Ad1 element with CREB/ATF factors, the Ad4/Ad5 element with SF-1/ERRα, and an AP-1 complex, while post-transcriptional regulation occurs through mRNA stabilization (e.g., by PCBs via an internal mRNA element) and microRNA targeting (miR-10b at the 3'-UTR), and epigenetic control by promoter DNA methylation modulates expression in adrenal adenomas.\"\n}\n```","stage2_raw":"```json\n{\n  \"mechanistic_narrative\": \"CYP11B1 is a mitochondrial cytochrome P450 enzyme that catalyzes the regio- and stereoselective 11β-hydroxylation of 11-deoxycortisol to cortisol, serving as the final and rate-limiting step of glucocorticoid biosynthesis in the adrenal zona fasciculata/reticularis [PMID:3499608, PMID:19029289]. The enzyme requires electrons from NADPH delivered via adrenodoxin reductase and adrenodoxin, and competes with CYP11A1 for this shared electron transfer chain [PMID:10411633, PMID:17935813]. Key residues in the I-helix region (positions 288, 301, 302, 320, 335) determine its strict 11β-hydroxylase regiospecificity and distinguish it from the aldosterone synthase activity of the paralog CYP11B2; mutagenesis of these residues interconverts the two enzymatic activities [PMID:8969896, PMID:9814482, PMID:9546661]. Loss-of-function mutations in CYP11B1 cause congenital adrenal hyperplasia due to 11β-hydroxylase deficiency, with residual enzymatic activity quantitatively determining disease severity, while chimeric CYP11B1/CYP11B2 genes arising from unequal crossing-over cause glucocorticoid-suppressible hyperaldosteronism [PMID:1518866, PMID:20089618, PMID:2022736].\",\n  \"teleology\": [\n    {\n      \"year\": 1987,\n      \"claim\": \"Cloning of CYP11B1 established the molecular identity and chromosomal location of the adrenal 11β-hydroxylase, resolving which gene product converts 11-deoxycortisol to cortisol.\",\n      \"evidence\": \"cDNA cloning from bovine and human adrenal libraries with sequence analysis and chromosomal mapping to 8q\",\n      \"pmids\": [\"3499608\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Crystal structure not yet determined\", \"Electron transfer partner interaction surfaces undefined\", \"Transcriptional regulation unknown\"]\n    },\n    {\n      \"year\": 1991,\n      \"claim\": \"Identification of the R448H mutation in the conserved heme-binding domain established that the heme-coordinating cysteine region is essential for catalytic activity, providing the first structure-function link for CYP11B1.\",\n      \"evidence\": \"PCR-selective amplification and sequencing in patients with 11β-hydroxylase deficiency, family segregation analysis\",\n      \"pmids\": [\"2022736\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Only one mutation characterized; scope of critical residues unknown\", \"No in vitro reconstitution of mutant enzyme\"]\n    },\n    {\n      \"year\": 1992,\n      \"claim\": \"Demonstration that chimeric CYP11B1/CYP11B2 genes cause glucocorticoid-suppressible hyperaldosteronism revealed that CYP11B1 regulatory sequences confer ACTH-dependent expression while CYP11B2 coding regions encode aldosterone synthase activity, explaining how gene conversion creates disease.\",\n      \"evidence\": \"Southern blotting and transfection of hybrid cDNAs with steroid product measurement\",\n      \"pmids\": [\"1518866\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Exact breakpoint positions of hybrid genes not fully mapped\", \"Crossover frequency unknown\"]\n    },\n    {\n      \"year\": 1993,\n      \"claim\": \"Systematic in vitro expression of disease-causing mutations showed that exons 6–8 encode functionally critical residues, while identification of AP-1 and Ad4BP/SF-1 binding sites in the promoter defined the transcriptional control architecture governing zone-specific and ACTH-responsive CYP11B1 expression.\",\n      \"evidence\": \"In vitro transfection in COS-7 cells with enzymatic activity measurement for mutations; EMSA, reporter assays, immunohistochemistry, and cotransfection of Ad4BP for promoter studies\",\n      \"pmids\": [\"8506298\", \"7565753\", \"8247022\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Chromatin-level regulation not addressed\", \"In vivo promoter occupancy not demonstrated\", \"Protein folding/stability effects of mutations not distinguished from catalytic effects\"]\n    },\n    {\n      \"year\": 1996,\n      \"claim\": \"Residue-swapping mutagenesis between CYP11B1 and CYP11B2 pinpointed I-helix positions 288, 301, 302, 320, and 335 as the key determinants of regiospecificity, establishing the molecular basis for why CYP11B1 performs only 11β-hydroxylation while CYP11B2 additionally catalyzes 18-hydroxylation and 18-oxidation.\",\n      \"evidence\": \"Site-directed mutagenesis with transfection and steroid product analysis by HPLC/RIA across multiple studies\",\n      \"pmids\": [\"8969896\", \"9814482\", \"9546661\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"No crystal structure to validate modeled substrate-binding orientation\", \"Dynamics of substrate positioning during multi-step catalysis unknown\"]\n    },\n    {\n      \"year\": 1998,\n      \"claim\": \"Characterization of ACTH-induced AP-1 compositional changes (from JunD/Fra-2 to c-Jun/c-Fos) established the signaling mechanism linking ACTH/cAMP to CYP11B1 transcriptional activation, showing Ad4BP is dispensable for ACTH induction in adrenocortical cells.\",\n      \"evidence\": \"Transient transfection, promoter-reporter assays, EMSA, and overexpression of AP-1 components in rat adrenocortical cells\",\n      \"pmids\": [\"9746364\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"In vivo chromatin immunoprecipitation not performed\", \"Contribution of CREB versus AP-1 not fully delineated\"]\n    },\n    {\n      \"year\": 1999,\n      \"claim\": \"Cotransfection experiments revealed that CYP11B1 and CYP11A1 compete for adrenodoxin-delivered electrons, demonstrating that electron supply is a limiting factor in mitochondrial steroidogenesis and suggesting a regulatory role for the shared electron transfer chain.\",\n      \"evidence\": \"Cotransfection of CYP11A1, CYP11B1, and adrenodoxin cDNAs into COS-1 cells with steroid product analysis\",\n      \"pmids\": [\"10411633\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Competition dynamics not measured in physiological adrenal context\", \"Stoichiometry of endogenous adrenodoxin relative to P450 demand unknown\", \"Species-specific differences complicate generalization\"]\n    },\n    {\n      \"year\": 2001,\n      \"claim\": \"Kinetic analysis of adrenodoxin mutants showed that CYP11B1 heme reduction is relatively insensitive to adrenodoxin C-terminal modifications compared to CYP11A1, revealing distinct protein-protein interaction requirements within the mitochondrial electron transfer chain.\",\n      \"evidence\": \"In vitro kinetic reconstitution with 8 adrenodoxin site-directed mutants measuring heme reduction rates\",\n      \"pmids\": [\"11459837\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"CYP11B1–adrenodoxin binding interface not structurally defined\", \"Effect on catalytic turnover (vs. single-electron transfer) not measured\"]\n    },\n    {\n      \"year\": 2008,\n      \"claim\": \"The Cyp11b1 knockout mouse confirmed the enzyme's non-redundant role as the sole source of glucocorticoid synthesis in vivo, recapitulating human 11β-hydroxylase deficiency with glucocorticoid insufficiency, DOC-driven mineralocorticoid excess, adrenal hyperplasia, and female infertility.\",\n      \"evidence\": \"Targeted gene knockout (exons 3–7 replaced) with urinary steroid profiling, immunocytochemistry, and phenotypic assessment\",\n      \"pmids\": [\"19029289\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Tissue-specific conditional knockout not performed\", \"Compensatory changes in CYP11B2 expression not fully characterized\"]\n    },\n    {\n      \"year\": 2010,\n      \"claim\": \"Quantitative genotype-phenotype correlations across multiple CYP11B1 mutations established that residual enzyme activity (<5% = classic disease; 25–40% = non-classic disease) is the primary determinant of clinical severity in 11β-hydroxylase deficiency.\",\n      \"evidence\": \"In vitro expression of seven novel mutations in COS-7 cells with quantitative activity measurement and 3D modeling\",\n      \"pmids\": [\"20089618\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Protein stability versus catalytic impairment not distinguished for all mutants\", \"Modifier genes or environmental factors not assessed\"]\n    },\n    {\n      \"year\": 2014,\n      \"claim\": \"Discovery that miR-10b directly targets the CYP11B1 3′-UTR and is induced by hypoxia/HIF-1α established a post-transcriptional regulatory layer linking oxygen sensing to cortisol biosynthetic capacity.\",\n      \"evidence\": \"Luciferase 3′-UTR reporter assay with miR-10b overexpression and knockdown in H295R cells\",\n      \"pmids\": [\"24768260\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"In vivo relevance of miR-10b regulation of CYP11B1 not demonstrated\", \"Other miRNAs targeting CYP11B1 not systematically surveyed\"]\n    },\n    {\n      \"year\": 2017,\n      \"claim\": \"Demonstration that CYP11B1 promoter hypomethylation drives cortisol overproduction in cortisol-producing adenomas linked cAMP pathway mutations (PRKACA, GNAS) to epigenetic derepression, adding an epigenetic dimension to CYP11B1 transcriptional control.\",\n      \"evidence\": \"Promoter CpG methylation analysis, luciferase reporter assays with methylated/unmethylated constructs, somatic mutation correlation in adenoma samples\",\n      \"pmids\": [\"28894201\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Causal directionality (mutation → demethylation → expression) not fully established\", \"Methylation dynamics during normal ACTH stimulation not characterized\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"A high-resolution crystal structure of CYP11B1 with substrate bound is still needed to validate the computationally modeled I-helix substrate-binding pocket and to understand the precise structural basis for regiospecificity versus CYP11B2.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"High\",\n      \"gaps\": [\"No experimental 3D structure of CYP11B1\", \"Transition-state geometry of 11β-hydroxylation unknown\", \"Structural basis for differential adrenodoxin interaction requirements versus CYP11A1 unresolved\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0016491\", \"supporting_discovery_ids\": [0, 5, 6, 10, 12, 14, 15, 16, 25, 26, 27, 31]},\n      {\"term_id\": \"GO:0140096\", \"supporting_discovery_ids\": [12, 14, 15]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005739\", \"supporting_discovery_ids\": [0, 9, 26]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-1430728\", \"supporting_discovery_ids\": [0, 9, 12, 14, 15, 26, 31]},\n      {\"term_id\": \"R-HSA-1643685\", \"supporting_discovery_ids\": [1, 2, 3, 5, 13, 27]}\n    ],\n    \"complexes\": [],\n    \"partners\": [\n      \"FDX1\",\n      \"FDXR\",\n      \"CYP11A1\",\n      \"NR5A1\",\n      \"JUN\",\n      \"FOS\",\n      \"ESRRA\"\n    ],\n    \"other_free_text\": []\n  }\n}\n```\n\n--- ROUND 2 (R2/R3, augmented corpus) ---\n\n```json\n{\n  \"mechanistic_narrative\": \"CYP11B1 is a mitochondrial cytochrome P450 (steroid 11β-hydroxylase) that catalyzes the final step of cortisol biosynthesis by converting 11-deoxycortisol to cortisol, receiving electrons from NADPH via the adrenodoxin reductase–adrenodoxin chain, with which it forms multiple productive complexes [PMID:18215163, PMID:2401360]. Substrate regioselectivity—distinguishing CYP11B1 (11β-hydroxylase) from the paralog CYP11B2 (aldosterone synthase)—is determined by a small cluster of residues in the I-helix region (positions 301–335), where single substitutions can confer 18-oxidase activity on CYP11B1 [PMID:9546661, PMID:8969896]. Zona fasciculata–specific transcription is driven by cooperative action of a CRE/Ad1 element bound by CREB/ATF factors, an Ad4 element bound by SF-1, an Ad5 element occupied by ERRα, and an AP-1 complex whose composition shifts upon ACTH stimulation, while post-transcriptional regulation occurs through mRNA stabilization and miR-10b–mediated repression, and promoter DNA methylation modulates expression in cortisol-producing adenomas [PMID:11196473, PMID:8247022, PMID:22079243, PMID:9746364, PMID:24768260, PMID:28894201]. Loss-of-function mutations cause congenital adrenal hyperplasia due to 11β-hydroxylase deficiency, with residual enzymatic activity directly correlating with clinical severity, and Cyp11b1-knockout mice recapitulate glucocorticoid deficiency, mineralocorticoid excess, and hypertension [PMID:20089618, PMID:19029289].\",\n  \"teleology\": [\n    {\n      \"year\": 1987,\n      \"claim\": \"Establishing that CYP11B1 encodes a mitochondrial cytochrome P450 with steroid 11β-hydroxylase activity resolved the molecular identity of the enzyme responsible for cortisol's final biosynthetic step.\",\n      \"evidence\": \"cDNA cloning, sequencing, and chromosomal mapping to 8q from bovine/human adrenal libraries\",\n      \"pmids\": [\"3499608\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Enzymatic activity not yet demonstrated from the cloned cDNA\", \"Paralogous gene (CYP11B2) not yet distinguished\"]\n    },\n    {\n      \"year\": 1990,\n      \"claim\": \"Functional expression in heterologous cells demonstrated that CYP11B1 has exclusively 11β-hydroxylase activity (cortisol synthesis) and cannot synthesize aldosterone, definitively distinguishing it from CYP11B2 despite 93% sequence identity.\",\n      \"evidence\": \"COS-7 transient transfection with steroid conversion assays for CYP11B1 vs CYP11B2; genomic structure comparison\",\n      \"pmids\": [\"2401360\", \"2592361\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Structural determinants of substrate selectivity unknown\", \"Electron-transfer partner requirements not quantified\"]\n    },\n    {\n      \"year\": 1993,\n      \"claim\": \"Systematic expression of disease-causing mutations revealed that residues in exons 6–8—including the heme-ligand-proximal Arg-448—are essential for catalysis, mapping functionally critical domains before any crystal structure was available.\",\n      \"evidence\": \"In vitro COS cell expression of five missense and one nonsense mutation with steroid conversion assays; family segregation studies\",\n      \"pmids\": [\"8506298\", \"2022736\", \"7903314\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Three-dimensional structure not determined\", \"Mechanism by which individual residues contribute to catalysis unresolved\"]\n    },\n    {\n      \"year\": 1993,\n      \"claim\": \"Identification of Ad4BP (SF-1) as the steroidogenic cell–specific transcription factor driving CYP11B1 promoter activity via the Ad4 element explained why this gene is expressed only in adrenocortical cells.\",\n      \"evidence\": \"Cotransfection of Ad4BP expression vector restores CYP11B1 reporter activity in non-steroidogenic cells; immunoblot confirmation\",\n      \"pmids\": [\"8247022\", \"1336011\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Additional cis-elements (CRE/Ad1, AP-1) not yet integrated into a unified regulatory model\", \"In vivo chromatin context not assessed\"]\n    },\n    {\n      \"year\": 1996,\n      \"claim\": \"Reciprocal mutagenesis at I-helix positions (296, 301, 302, 320, 335) between CYP11B1 and CYP11B2 showed that a handful of residues in this region determine whether the enzyme performs 11β-hydroxylation or aldosterone synthesis, resolving the structural basis of paralog divergence.\",\n      \"evidence\": \"Site-directed mutagenesis with COS cell expression and steroid product profiling\",\n      \"pmids\": [\"8969896\", \"9546661\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Crystal structure needed to explain how these residues position substrate\", \"Residues 301–335 necessary but possibly not sufficient for full selectivity switch\"]\n    },\n    {\n      \"year\": 1998,\n      \"claim\": \"ACTH-stimulated CYP11B1 transcription was shown to operate through an AP-1 site whose factor composition shifts from constitutive JunD/Fra-2 to induced c-Jun/c-Fos via cAMP, integrating hormonal signaling with zona fasciculata–specific expression.\",\n      \"evidence\": \"Promoter mutant transfection, AP-1 supershift EMSA, and in vivo ACTH treatment in rat adrenal\",\n      \"pmids\": [\"9746364\", \"7565753\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Chromatin remodeling events at the endogenous locus not examined\", \"Relative contribution of AP-1 vs CRE/Ad1 to ACTH response not quantified in human cells\"]\n    },\n    {\n      \"year\": 2001,\n      \"claim\": \"Stopped-flow kinetics with adrenodoxin mutants revealed that CYP11B1 and CYP11A1 have distinct electron-transfer requirements, and Biacore data later showed CYP11B1 possesses more than one adrenodoxin-binding site, explaining how multiple productive complexes form.\",\n      \"evidence\": \"Stopped-flow CO-complex kinetics with adrenodoxin variants; SPR (Biacore) binding of purified CYP11B1\",\n      \"pmids\": [\"11459837\", \"18215163\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Stoichiometry and structural arrangement of the multi-adrenodoxin complex not resolved\", \"In vivo relevance of multiple binding sites not tested\"]\n    },\n    {\n      \"year\": 2008,\n      \"claim\": \"A Cyp11b1-knockout mouse confirmed the enzyme's non-redundant in vivo role: loss of 11β-hydroxylase causes glucocorticoid deficiency, DOC-driven mineralocorticoid excess with hypertension, adrenal hyperplasia, and female infertility, phenocopying human 11β-hydroxylase deficiency.\",\n      \"evidence\": \"Targeted exon 3–7 replacement; urinary steroid profiling, blood pressure, reproductive phenotyping\",\n      \"pmids\": [\"19029289\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Rescue experiments not performed\", \"Sex-specific phenotypic mechanisms (anovulation) not dissected molecularly\"]\n    },\n    {\n      \"year\": 2010,\n      \"claim\": \"Quantitative in vitro activity measurement of classic and non-classic disease mutations established that residual enzyme activity directly predicts clinical severity, providing a mechanistic framework for genotype–phenotype correlation.\",\n      \"evidence\": \"COS7 expression of seven mutations; steroid conversion assay correlated with clinical phenotype\",\n      \"pmids\": [\"20089618\", \"9302260\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Protein stability versus catalytic impairment not distinguished for all mutations\", \"Effects of compound heterozygosity on net activity not modeled\"]\n    },\n    {\n      \"year\": 2017,\n      \"claim\": \"Epigenetic regulation was added to the CYP11B1 regulatory model when promoter DNA hypomethylation was shown to increase CYP11B1 expression in cortisol-producing adenomas, linking somatic PRKACA/GNAS mutations to epigenetic de-repression.\",\n      \"evidence\": \"Bisulfite sequencing of adenoma vs. normal adrenal; methylated reporter assay; somatic mutation genotyping\",\n      \"pmids\": [\"28894201\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Causal direction (does mutation cause demethylation or vice versa?) not established by intervention\", \"Methylation dynamics during normal adrenal zonation unexplored\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"No experimentally determined crystal or cryo-EM structure of human CYP11B1 has been reported; structural understanding still relies on homology models, leaving the precise geometry of the substrate-binding pocket and the multi-adrenodoxin interaction surface unresolved.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Experimental 3D structure not available\", \"Molecular dynamics of substrate access channel and product release not characterized\", \"In vivo regulation by adrenal zonation-specific chromatin architecture not determined\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0016491\", \"supporting_discovery_ids\": [0, 2, 8, 15, 17, 19, 28, 29, 30]},\n      {\"term_id\": \"GO:0140096\", \"supporting_discovery_ids\": [2, 15, 17, 19, 28]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005739\", \"supporting_discovery_ids\": [0, 10, 29]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-1430728\", \"supporting_discovery_ids\": [0, 2, 15, 17, 19, 28, 29, 34]},\n      {\"term_id\": \"R-HSA-1643685\", \"supporting_discovery_ids\": [3, 5, 6, 8, 16, 30, 36]}\n    ],\n    \"complexes\": [],\n    \"partners\": [\n      \"FDX1\",\n      \"FDXR\",\n      \"NR5A1\",\n      \"CREB1\",\n      \"ATF2\",\n      \"JUN\",\n      \"ESRRA\"\n    ],\n    \"other_free_text\": []\n  }\n}\n```"}